Search

Your search keyword '"R, Zanetti"' showing total 566 results
Start Over Author "R, Zanetti"
566 results on '"R, Zanetti"'

4. Effects of resistance training on muscle strength, body composition and immune-inflammatory markers in people living with HIV: a systematic review and Meta-analysis of randomized controlled trials

Author

Hugo R. Zanetti, Leandro T. P. Lopes, Alexandre Gonçalves, Vitor L. Soares, Weverton F. Soares, Adrian V. Hernandez, Gary Tse, Tong Liu, Giuseppe Biondi-Zoccai, Leonardo Roever, and Edmar L. Mendes

Subjects
hiv/aids, strength training, lean body mass, lymphocyte cd4+, tnf-α, il-6, Infectious and parasitic diseases, RC109-216
Abstract

Purpose: The purpose of this review is to evaluate the effect of resistance training (RT) as a unique intervention on muscle strength, body composition, and immune-inflammatory markers in people living with HIV (PLHIV). Methods: The searches were conducted in seven databases and included published randomized clinical trials that assessed the effect of RT vs. no exercise on muscle strength, body composition, and immune-inflammatory markers in PLHIV until June 2021. Random effects meta-analyses of mean differences (MD) and their 95% confidence intervals (CI) were performed, and the effect size was estimated by Hedges’ g test. Results: Seven RCTs were included (n= 258 PLHIV) and the study duration lasted between six and 24 weeks. In comparison to no exercise, RT improved muscle strength in bench press (MD 10.69 kg, 95%IC 3.44 to 17.93, p= 0.004, g =2.42) and squat (MD 22.66 kg, 95%IC 7.82 to 37.50, p= 0.003, g = 3.8) exercises, lean body mass (MD 2.96 kg, 95%CI 0.98 to 4.94, p= 0.003, g = 1.99), fat body mass(MD −2.67 kg; 95%CI −4.95 to −0.39, p= 0.02, g=-0.99), body fat percentage (MD −3.66%, 95%CI −6.04 to −1.29, p= 0.003, g=-1.99) and CD4+ cells count(MD 100.15 cells/mm3, 95%CI 12.21 to 188.08, p = 0.03, g = 2.91) in PLHIV. There was no effect of RT on IL-6 (MD −1.18 pg/mL, 95%CI −3.71 to 1.35, p = 0.36, g = 0.001) and TNF-α (MD −4.76 pg/mL, 95%CI −10.81 to 1.29, p = 0.12, g=-1.3) concentrations in PLHIV. Conclusions: RT as a unique intervention improves muscle strength, body composition and CD4+ count cells in PLHIV.

Published
2021
Full Text
View/download PDF

9. Hepatitis B Vaccination: A Historical Overview with a Focus on the Italian Achievements

Author

Luisa Romano’ and Alessandro R. Zanetti

Subjects
hepatitis B, HBV, vaccine, vaccination, immunological memory, humoral immunity, Microbiology, QR1-502
Abstract

Vaccination is the most effective way to control and prevent acute and chronic hepatitis B, including cirrhosis and HCC, on a global scale. According to WHO recommendations, 190 countries in the world have introduced hepatitis B vaccination into their national childhood immunization programs with an excellent profile of safety, immunogenicity, and effectiveness. Following vaccination, seroprotection rates are close to 100% in healthy children and over 95% in healthy adults. Persistence of anti-HBs is related to the antibody peak achieved after vaccination. The peak is higher the longer the antibody duration is. Loss of anti-HBs does not necessarily mean loss of immunity since most vaccinated individuals retain immune memory for HBsAg and rapidly develop strong anamnestic responses when boosted. Evidence indicates that the duration of protection can persist for at least 35 years after priming. Hence, booster doses of vaccines are currently not recommended to sustain long-term immunity in healthy vaccinated individuals. In Italy, vaccination against hepatitis B is met with success. In 2020, Italy became one of the first countries in Europe to be validated for achieving the WHO regional hepatitis B control targets.

Published
2022
Full Text
View/download PDF

10. Virus-Derived Chemokine Modulating Protein Pre-Treatment Blocks Chemokine–Glycosaminoglycan Interactions and Significantly Reduces Transplant Immune Damage

Author

Isabela R. Zanetti, Michelle Burgin, Liqiang Zhang, Steve T. Yeh, Sriram Ambadapadi, Jacquelyn Kilbourne, Jordan R. Yaron, Kenneth M. Lowe, Juliane Daggett-Vondras, David Fonseca, Ryan Boyd, Dara Wakefield, William Clapp, Efrem Lim, Hao Chen, and Alexandra Lucas

Subjects
antisense, chemokine, glycosaminoglycans, inflammation, kidney, M-T7, Medicine
Abstract

Immune cell invasion after the transplantation of solid organs is directed by chemokines binding to glycosaminoglycans (GAGs), creating gradients that guide immune cell infiltration. Renal transplant is the preferred treatment for end stage renal failure, but organ supply is limited and allografts are often injured during transport, surgery or by cytokine storm in deceased donors. While treatment for adaptive immune responses during rejection is excellent, treatment for early inflammatory damage is less effective. Viruses have developed highly active chemokine inhibitors as a means to evade host responses. The myxoma virus-derived M-T7 protein blocks chemokine: GAG binding. We have investigated M-T7 and also antisense (ASO) as pre-treatments to modify chemokine: GAG interactions to reduce donor organ damage. Immediate pre-treatment of donor kidneys with M-T7 to block chemokine: GAG binding significantly reduced the inflammation and scarring in subcapsular and subcutaneous allografts. Antisense to N-deacetylase N-sulfotransferase1 (ASONdst1) that modifies heparan sulfate, was less effective with immediate pre-treatment, but reduced scarring and C4d staining with donor pre-treatment for 7 days before transplantation. Grafts with conditional Ndst1 deficiency had reduced inflammation. Local inhibition of chemokine: GAG binding in donor organs immediately prior to transplant provides a new approach to reduce transplant damage and graft loss.

Published
2022
Full Text
View/download PDF

11. Evaluation of a wheel-based seismic acquisition system for a planetary rover

Author

J. M. Lorenzo, A. Bates, D. A. Patterson, C. Sun, T. A. Douglas, S. Karunatillake, P. M. Bremner, M. R. Zanetti, H. F. Haviland, R. C. Weber, and A. J. Gemer

Subjects
Geophysics, Geology
Abstract

Prior to using in-situ planetary resources, efficient mapping of geochemical and physical characteristics of the near surface will be required. As part of an integrated geophysical instrument suite on exploration and prospecting vehicles, we investigated the suitability of seismic piezo-sensors rigidly mounted on the interior of a generic rover wheel. Factors that can compromise proper data acquisition for this system include the natural mechanical resonance of the wheel and wheel-to-ground coupling. We characterized the natural resonance frequency bands of a generic wheel with an electromagnetic shaker. We also collected seismic shot gathers for subsequent seismic surface-wave analysis using a wheel in both a dry, laboratory sand tank (1.8 × 1.8 × 0.6 m) and in frozen loess soils within the United States Army Corps of Engineers Permafrost Tunnel in Alaska. For our wheel, self-weighted coupling to the ground was found to be adequate, although suitable wheelbase dimensions can constrain field acquisition geometries. In unconsolidated sediments, represented by medium sand (0.25–0.5 mm), wheel resonance of 1 kHz does not affect the fundamental mode used in shear-wave-velocity-to-depth inversion. When analyzed, shot-gather data collected from both wheel-mounted sensors and sand-planted sensors, in loose dry sand, effectively captured similar fundamental surface-wave modes. This is evident in frequency-versus-phase velocity dispersion images. Because narrow frequency bands of wheel resonance exhibit a high signal-to-noise ratio, they also readily detect lateral attenuation changes. Thus, wheel resonance can also be used to capture soil attenuation changes, including those produced when pore H2O ice acts to cement the regolith or loose-grained soils.

Published
2022
Full Text
View/download PDF

12. A Defective Crosstalk Between Neurons and Müller Glial Cells in the rd1 Retina Impairs the Regenerative Potential of Glial Stem Cells

Author

Yanel A. Volonté, Harmonie Vallese-Maurizi, Marcos J. Dibo, Victoria B. Ayala-Peña, Andrés Garelli, Samanta R. Zanetti, Axel Turpaud, Cheryl Mae Craft, Nora P. Rotstein, Luis E. Politi, and Olga L. German

Subjects
Müller glial cells, stem cells, retinal degeneration, retinal regeneration, photoreceptors, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Müller glial cells (MGC) are stem cells in the retina. Although their regenerative capacity is very low in mammals, the use of MGC as stem cells to regenerate photoreceptors (PHRs) during retina degenerations, such as in retinitis pigmentosa, is being intensely studied. Changes affecting PHRs in diseased retinas have been thoroughly investigated; however, whether MGC are also affected is still unclear. We here investigated whether MGC in retinal degeneration 1 (rd1) mouse, an animal model of retinitis pigmentosa, have impaired stem cell properties or structure. rd1 MGC showed an altered morphology, both in culture and in the whole retina. Using mixed neuron-glial cultures obtained from newborn mice retinas, we determined that proliferation was significantly lower in rd1 than in wild type (wt) MGC. Levels of stem cell markers, such as Nestin and Sox2, were also markedly reduced in rd1 MGC compared to wt MGC in neuron-glial cultures and in retina cryosections, even before the onset of PHR degeneration. We then investigated whether neuron-glial crosstalk was involved in these changes. Noteworthy, Nestin expression was restored in rd1 MGC in co-culture with wt neurons. Conversely, Nestin expression decreased in wt MGC in co-culture with rd1 neurons, as occurred in rd1 MGC in rd1 neuron-glial mixed cultures. These results imply that MGC proliferation and stem cell markers are reduced in rd1 retinas and might be restored by their interaction with “healthy” PHRs, suggesting that alterations in rd1 PHRs lead to a disruption in neuron-glial crosstalk affecting the regenerative potential of MGC.

Published
2019
Full Text
View/download PDF

13. Mammographic breast density and survival in women with invasive breast cancer

Author

Carlo La Vecchia, Greta Carioli, R. Zanetti, Stefano Rosso, and Margherita Pizzato

Subjects
Oncology, Invasive breast cancer, Breast density, Survival, Breast cancer prognostic factors, Population-based data, medicine.medical_specialty, Cancer Research, Settore MED/06 - Oncologia Medica, business.industry, Settore MED/42 - Igiene Generale e Applicata, Breast Neoplasms, medicine.disease, Settore MED/01 - Statistica Medica, Breast cancer, Mammographic breast density, Risk Factors, Internal medicine, Medicine, Humans, Female, business, Breast Density, Mammography
Abstract

Purpose: Mammographic breast density (BD) is strongly associated to breast cancer (BC) risk; however, its association with survival is unclear.Methods: Using data from the Piedmont Cancer Registry (Registro Tumori Piemonte), we identified 693 women diagnosed with primary invasive BC between 2009-2014. We applied the Kaplan-Meier method to estimate overall survival in strata of BD and the log-rank test to assess survival differences. We evaluated the hazard ratios (HRs) of death using Cox proportional hazards model and HRs of BC-related and other causes of death using the cause-specific hazards regression model. Models included terms for BD (assessed according to the Breast Imaging Reporting and Data System [BI-RADS] density classification) and were adjusted for selected patient and tumour characteristics.Results: There were102 deaths, of which 49 were from BC. After 5 years, the overall survival was 70% in women with BI-RADS 1, 85% in those with BI-RADS 2, about 95% in those with BI-RADS 3-4 (p Conclusion: In women with BC, low BD has a negative prognostic impact.

Published
2022
Full Text
View/download PDF

15. Mouse Models of Renal Allograft Transplant Rejection: Methods to Investigate Chemokine-GAG Interaction and Therapeutic Blockade

Author

Isabela R, Zanetti, Liqiang, Zhang, Michelle, Burgin, Jacquelyn, Kilbourne, Jordan R, Yaron, David, Fonseca, and Alexandra R, Lucas

Subjects
Graft Rejection, Mice, Disease Models, Animal, Postoperative Complications, Animals, Chemokines, Allografts, Kidney Transplantation, Glycosaminoglycans
Abstract

Chemokine-glycosaminoglycan (GAG) interactions direct immune cell activation and invasion, e.g., directing immune cells to sites of infection or injury, and are central to initiating immune responses. Acute innate and also adaptive or antibody-mediated immune cell responses both drive damage to kidney transplants. These immune responses are central to allograft rejection and transplant failure. While treatment for acute rejection has advanced greatly, ongoing or chronic immune damage from inflammation and antibody-mediated rejection remains a significant problem, leading to transplant loss. There are limited numbers of organs available for transplant, and preventing chronic graft damage will allow for longer graft stability and function, reducing the need for repeat transplantation. Chemokine-GAG interactions are the basis for initial immune responses, forming directional gradients that allow immune cells to traverse the vascular endothelium and enter engrafted organs. Targeting chemokine-GAG interactions thus has the potential to reduce immune damage to transplanted kidneys.Mouse models for renal transplant are available, but are complex and require extensive microsurgery expertise. Here we describe simplified subcapsular and subcutaneous renal allograft transplant models, for rapid assessment of the roles of chemokine-GAG interactions during allograft surgery and rejection. These models are described, together with treatment using a unique chemokine modulating protein (CMP) M-T7 that disrupts chemokine-GAG interactions.

Published
2022

16. Approximate zero-crossing: a new interpretable, highly discriminative and low-complexity feature for EEG and iEEG seizure detection

Author

R Zanetti, U Pale, T Teijeiro, D Atienza, and European Commission

Subjects
Epilepsy, iEEG, Biomedical Engineering, Electroencephalography, Seizure detection, Feature Engineering, Cellular and Molecular Neuroscience, Seizures, Zero-crossing, Machine learning, Humans, EEG, Electrocorticography, Algorithms
Abstract

Objective. Long-term monitoring of people with epilepsy based on electroencephalography (EEG) and intracranial EEG (iEEG) has the potential to deliver key clinical information for personalised epilepsy treatment. More specifically, in outpatient settings, the available solutions are not satisfactory either due to poor classification performance or high complexity to be executed in resource-constrained devices (e.g. wearable systems). Therefore, we hypothesize that obtaining high discriminative features is the main avenue to improve low-complexity seizure-detection algorithms.Approach. Inspired by how neurologists recognize ictal EEG data, and to tackle this problem by targeting resource-constrained wearable devices, we introduce a new interpretable and highly discriminative feature for EEG and iEEG, namely approximate zero-crossing (AZC). We obtain AZC by applying a polygonal approximation to mimic how our brain selects prominent patterns among noisy data and then using a zero-crossing count as a measure of the dominating frequency. By employing Kullback-Leiber divergence, leveraging CHB-MIT and SWEC-ETHZ iEEG datasets, we compare the AZC discriminative power against a set of 56 classical literature features (CLF). Moreover, we assess the performances of a low-complexity seizure detection method using only AZC features versus employing the CLF set.Main results. Three AZC features obtained with different approximation thresholds are among the five with the highest median discriminative power. Moreover, seizure classification based on only AZC features outperforms an equivalent CLF-based method. The former detects 102 and 194 seizures, against 99 and 161 for the latter (CHB-MIT and SWEC-ETHZ, respectively). Moreover, the AZC-based method keeps a similar false-alarm rate (i.e. an average of 2.1 and 1.0, against 2.0 and 0.5, per day).Significance. We propose a new feature and demonstrate its capability in seizure classification for both scalp and intracranial EEG. We envision the use of such a feature to improve outpatient monitoring with resource-constrained devices. This work was supported in part by the ML-Edge Swiss National Science Foundation (NSF) Research under Project (GA 20 002 0182 009/1), in part by the PEDESITE Swiss NSF Sinergia project (GA No. SCRSII5 193 813/1), in part by the European Union's Horizon 2020 research and innovation programme under the Marie Skłlodowska-Curie under Grant Agreement 754 354, and in part by the Maria Zambrano fellowship (MAZAM21/29) from the University of Basque Country and the Spanish Ministry of Universities, funded by the European Union-Next-GenerationEU.

Published
2022

17. Frequency of respiratory virus infections and next-generation analysis of influenza A/H1N1pdm09 dynamics in the lower respiratory tract of patients admitted to the ICU.

Author

Antonio Piralla, Francesca Rovida, Alessia Girello, Marta Premoli, Francesco Mojoli, Mirko Belliato, Antonio Braschi, Giorgio Iotti, Elena Pariani, Laura Bubba, Alessandro R Zanetti, and Fausto Baldanti

Subjects
Medicine, Science
Abstract

Recent molecular diagnostic methods have significantly improved the diagnosis of viral pneumonia in intensive care units (ICUs). It has been observed that 222G/N changes in the HA gene of H1N1pdm09 are associated with increased lower respiratory tract (LRT) replication and worse clinical outcome. In the present study, the frequency of respiratory viruses was assessed in respiratory samples from 88 patients admitted to 16 ICUs during the 2014-2015 winter-spring season in Lombardy. Sixty-nine out of 88 (78.4%) patients were positive for a respiratory viral infection at admission. Of these, 57/69 (82.6%) were positive for influenza A (41 A/H1N1pdm09 and 15 A/H3N2), 8/69 (11.6%) for HRV, 2/69 (2.9%) for RSV and 2/69 (2.9%) for influenza B. Phylogenetic analysis of influenza A/H1N1pdm09 strains from 28/41 ICU-patients and 21 patients with mild respiratory syndrome not requiring hospitalization, showed the clear predominance of subgroup 6B strains. The median influenza A load in LRT samples of ICU patients was higher than that observed in the upper respiratory tract (URT) (p

Published
2017
Full Text
View/download PDF

18. Clinical Data as an Adjunct to Ultrasound Reduces the False-Negative Malignancy Rate in BI-RADS 3 Breast Lesions

Author

S. Ackermann, C.-A. Schoenenberger, and R. Zanetti-Dällenbach

Subjects
breast ultrasound, bi-rads, breast cancer, false-negative, cancer rate, Medicine, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Purpose: Ultrasound (US) is a well-established diagnostic procedure for breast examination. We investigated the malignancy rate in solid breast lesions according to their BI-RADS classification with a particular focus on false-negative BI-RADS 3 lesions. We examined whether patient history and clinical findings could provide additional information that would help determine further diagnostic steps in breast lesions. Materials and Methods: We conducted a retrospective study by exploring US BI-RADS in 1469 breast lesions of 1201 patients who underwent minimally invasive breast biopsy (MIBB) from January 2002 to December 2011. Results: The overall sensitivity and specificity of BI-RADS classification was 97.4% and 66.4%, respectively, with a positive (PPV) and negative predictive value (NPV) of 65% and 98%, respectively. In 506 BI-RADS 3 lesions, histology revealed 15 malignancies (2.4% malignancy rate), which corresponds to a false-negative rate (FNR) of 2.6%. Clinical evaluation and patient requests critically influenced the further diagnostic procedure, thereby prevailing over the recommendation given by the BI-RADS 3 classification. Conclusion: Clinical criteria including age, family and personal history, clinical examination, mammography and patient choice ensure adequate diagnostic procedures such as short-term follow-up or MIBB in patients with lesions classified as US-BI-RADS 3.

Published
2016
Full Text
View/download PDF

22. Abstract 13747: Targeting Urokinase-Type Plasminogen Activator (uPA) and the uPA Receptor, Reduces Vascular Inflammation and Lung Hemorrhage in Systemic Lupus and SARS CoV2 Infection in Mouse Models of Respiratory Distress Syndromes

Author

Liqiang Zhang, Jordan R Yaron, Lauren Schutz, Emily Aliskevich, Kyle Browder, Nicholas Saldevar, Isabela R Zanetti, Nora Elmadbouly, Honor Glenn, Yize Li, Karen Kibler, Brenda Hogue, Grant McFadden, and Alexandra R Lucas

Subjects
Physiology (medical), Cardiology and Cardiovascular Medicine
Abstract

Introduction: Acute respiratory distress syndromes with vascular inflammation and alveolar hemorrhage have high mortality and limited treatment. Autoimmune disease and severe viral infection cause vascular inflammation and hemorrhage. Serine protease coagulation pathways increase inflammatory cell activation and damage. Viruses have evolved highly effective immune modulating ser ine p roteinase in hibitors, serpins . Myxomavirus Serp-1 improves survival and reduces inflammation, vasculitis and lung hemorrhage in MHV68 gamma herpes infections (P < 0.01). Serp-1 also reduces Lupus alveolar hemorrhage (DAH) and proved safe and effective in a randomized, blinded, dose escalating trial in patients with coronary stent implant. Hypothesis: We hypothesize that treatment with PEGylated Serp-1 (PEGSerp-1) will reduce hemorrhage and inflammatory vasculitis in autoimmune and infectious lung disease. Methods: Pristane induced DAH and SARS-CoV-2 virus infections were treated with PEGSerp-1 in mouse models. Results: Serp-1 and PEGSerp-1 given daily IP for 14 days significantly reduced pristane induced DAH (N = 30 C57Bl/6 mice; P < 0.05) at 14 days follow up. PEGSerp-1 also reduced lung hemorrhage given for 7days treatment (N = 6 mice; P Conclusion: Treatment for vascular inflammation and hemorrhage in severe autoimmune and virus induced respiratory distress syndromes is very limited. Targeting thrombolytic and inflammatory serine protease uPA/ uPAR complex activation provides a new therapeutic approach to severe respiratory distress in autoimmune disease and viral infection.

Published
2021
Full Text
View/download PDF

23. A Low Power Voltage Sag Compensator

Author

Fernando O. Martinz, Mauricio Galassi, Antonio R. Giaretta, Marco A. Oliveira, Fabiana A.T. Silva, Mario Masuda, Simão Copeliovitch, Eric R. Zanetti, Eduardo G. Lima, Josué Camargo, Se Un Ahn, Lourenço Matakas Jr., Wilson Komatsu, and José A. Jardini

Subjects
dsp controlled converter, dynamic voltage restorer (dvr), power quality, voltage sags, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

The increasing use of voltage variation sensitive loads in industrial applications nowadays has brought a real concern about interruption costs and damages in complex production lines. This paper presents a power-electronic–based device which compensates voltage sags, restoring the load voltage to acceptable values through a series connected injection transformer. The ratings and power requirements of a low-power voltage sag compensator, also known as Dynamic Voltage Restorer (DVR) are derived, as well as its deadbeat control algorithm implemented in a Digital Signal Processor (DSP). Finally, simulation and experimental results of a 5-kVA prototype are presented.

Published
2006
Full Text
View/download PDF

24. Serial changes in plasma levels of cytokines in patients with coronary artery disease

Author

Roberto H Heinisch, Carlos R Zanetti, Fabiano Comin, Juliano L Fernandes, José A Ramires, and Carlos V Serrano Jr

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Roberto H Heinisch1, Carlos R Zanetti1, Fabiano Comin1, Juliano L Fernandes2, José A Ramires2, Carlos V Serrano Jr21Federal University of Santa Catarina, Florianópolis, Brazil; 2Heart Institute (InCor), University of São Paulo Medical School, São Paulo, BrazilObjectives: Inflammation is known to be a major determinant of the progression of coronary artery disease (CAD). In the present study we have evaluated the plasma levels of cytokines – tumor necrosis factor-α (TNF), interleukin-1α (IL-1), interleukin-6 (IL-6), interferon-γ (IFN), and interleukin-10 (IL-10) – to examine the association between these cytokines and C-reactive protein (CRP) in patients with CAD.Methods: Patients with acute coronary syndromes (ACS; n = 20) were compared with patients with stable angina (SA; n = 20) and with control volunteers (C; n = 20). Blood samples were collected at the time of admission from all patients and 15 and 30 days thereafter.Results: CRP levels (20.8 ± 8.8 mg/L) (mean ± SEM) were higher at baseline in ACS than SA patients (4.1 ± 0.8 mg/L) or the control subjects (5.1 ± 1.8 mg/L) (p < 0.05). At admission, IL-6 was detected in 50% of the ACS patients and 5% of the SA patients or control subjects, while TNF was detected in 35% of the ACS and SA patients but only in 5% of control subjects. Subsequently, IL-6 levels declined and were no longer detectable, while TNF levels increased among ACS patients at all time periods tested when compared with other patients. The presence of IL-1 and IL-10 were not detectable in the blood samples examined, and IFN could only be detected in the ACS group. A significant correlation was observed between IL-6 and CRP levels (r = 0.4; p < 0.01) in all groups. There were no correlations among any of the other cytokines and CRP levels.Conclusions: Our study demonstrates raised levels of TNF, IL6, IFN, and CRP in patients with ACS and a positive correlation between IL6 and CRP but not with the other cytokines. Keywords: cytokines, tumor necrosis factor-α, interleukin-6, C-reactive protein, coronary artery disease

Published
2005

25. Association of <scp>IRF</scp> 4 single‐nucleotide polymorphism rs12203592 with melanoma‐specific survival

Author

Anne E. Cust, Sarah V. Ward, David C. Gibbs, Colin B. Begg, Stefano Rosso, P.A. Kanetsky, Li Luo, Nancy E. Thomas, Hoda Anton-Culver, Marianne Berwick, Irene Orlow, Terence Dwyer, Richard P. Gallagher, R. Zanetti, and Stephen B. Gruber

Subjects
Genetics, Skin Neoplasms, Genotype, Single-nucleotide polymorphism, Melanoma specific survival, Dermatology, Biology, Polymorphism, Single Nucleotide, Article, Survival Rate, Interferon Regulatory Factors, Humans, Genetic Predisposition to Disease, Melanoma, IRF4
Abstract

We have previously shown that the functional melanoma risk variant rs12203592 in interferon regulatory factor-4 (IRF4) was associated with increased Breslow thickness, an important prognostic indicator for melanoma. In line with this, a recent study found evidence for an association between the minor T allele of this single nucleotide polymorphism (SNP) and melanoma-specific survival in patients from two European hospitals.

Published
2020
Full Text
View/download PDF

27. Integrated proteomics identified up-regulated focal adhesion-mediated proteins in human squamous cell carcinoma in an orthotopic murine model.

Author

Daniela C Granato, Mariana R Zanetti, Rebeca Kawahara, Sami Yokoo, Romênia R Domingues, Annelize Z Aragão, Michelle Agostini, Marcelo F Carazzolle, Ramon O Vidal, Isadora L Flores, Johanna Korvala, Nilva K Cervigne, Alan R S Silva, Ricardo D Coletta, Edgard Graner, Nicholas E Sherman, and Adriana F Paes Leme

Subjects
Medicine, Science
Abstract

Understanding the molecular mechanisms of oral carcinogenesis will yield important advances in diagnostics, prognostics, effective treatment, and outcome of oral cancer. Hence, in this study we have investigated the proteomic and peptidomic profiles by combining an orthotopic murine model of oral squamous cell carcinoma (OSCC), mass spectrometry-based proteomics and biological network analysis. Our results indicated the up-regulation of proteins involved in actin cytoskeleton organization and cell-cell junction assembly events and their expression was validated in human OSCC tissues. In addition, the functional relevance of talin-1 in OSCC adhesion, migration and invasion was demonstrated. Taken together, this study identified specific processes deregulated in oral cancer and provided novel refined OSCC-targeting molecules.

Published
2014
Full Text
View/download PDF

29. Twenty years of universal vaccination against hepatitis B in Italy: achievements and challanges

Author

Luisa Romano', Sara Paladini, and Alessandro R. Zanetti

Subjects
HBV, hepatitis B, vaccination, long-term immunity, Public aspects of medicine, RA1-1270
Abstract

Viral hepatitis B is a vaccine-preventable disease. Vaccination has proved to be safe and highly effective in reducing the incidence, the carrier rate and HBV-related mortality on a global scale. In Italy, universal vaccination against hepatitis B started in 1991 in infants as well as in adolescents, providing an outstanding record of safety and effectiveness. Within a few years, over 95% coverage was consistently reported. Today, some 17 million people are immune against hepatitis B and their immunity has been shown to be long-lasting. At present, no booster is required in healthy vaccinated people to sustain protection. Surveillance data from Italy have shown a clear overall decline in hepatitis B among successfully vaccinated individuals. Furthermore, a generation of children and young people (at present cohorts ranging from 0 to 32 years) is emerging with practically no markers of HBV infection. Italy’s vaccination programme has resulted in substantial progress being made towards the prevention and control of hepatitis B. The vaccination programme must continue. Maintaining mandatory vaccination of infants and increasing HBV vaccination coverage in high-risk groups, including households of HBsAg carriers as well as immigrants, remain a priority for the future.

Published
2012
Full Text
View/download PDF

30. Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration.

Author

Annelize Z B Aragão, Marília Belloni, Fernando M Simabuco, Mariana R Zanetti, Sami Yokoo, Romênia R Domingues, Rebeca Kawahara, Bianca A Pauletti, Anderson Gonçalves, Michelle Agostini, Edgard Graner, Ricardo D Coletta, Jay W Fox, and Adriana F Paes Leme

Subjects
Medicine, Science
Abstract

The extracellular milieu is comprised in part by products of cellular secretion and cell surface shedding. The presence of such molecules of the sheddome and secretome in the context of the extracellular milieu may have important clinical implications. In cancer they have been hypothesized to play a role in tumor growth and metastasis. The objective of this study was to evaluate whether the sheddome/secretome from two cell lines could be correlated with their potential for tumor development. Two epithelial cell lines, HaCaT and SCC-9, were chosen based on their differing abilities to form tumors in animal models of tumorigenesis. These cell lines when stimulated with phorbol-ester (PMA) showed different characteristics as assessed by cell migration, adhesion and higher gelatinase activity. Proteomic analysis of the media from these treated cells identified interesting, functionally relevant differences in their sheddome/secretome. Among the shed proteins, soluble syndecan-1 was found only in media from stimulated tumorigenic cells (SCC-9) and its fragments were observed in higher amount in the stimulated tumorigenic cells than stimulated non-tumorigenic cells (HaCaT). The increase in soluble syndecan-1 was associated with a decrease in membrane-bound syndecan-1 of SCC-9 cells after PMA stimuli. To support a functional role for soluble syndecan-1 fragments we demonstrated that the synthetic syndecan-1 peptide was able to induce cell migration in both cell lines. Taken together, these results suggested that PMA stimulation alters the sheddome/secretome of the tumorigenic cell line SCC-9 and one such component, the syndecan-1 peptide identified in this study, was revealed to promote migration in these epithelial cell lines.

Published
2012
Full Text
View/download PDF

31. Immunomodulatory effect of glucan on the response to experimental antirabies vaccination Efeito imunomodulatório da glucana na resposta à vacinação anti-rábica experimental

Author

Milene S. Tino, Maria L. Carrieri, Carlos R Zanetti, Nelson F. Mendes, and Octavio A.C. Pereira

Subjects
Glucan, Antirabies vaccination, Rabies, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

The objective of lhe present study was to determine the stimulatory response to antirabies vaccination promoted by glucan in mice. Glucan increased both resistance to infection and antibody titres and this effect was more evident when glucan was used at dose of 0.5 mg, administered intraperitoneally before, during and after immunization and when the challenge virus was applied to the foot-pad.No presente trabalho verificou-se a atividade estimuladora da resposta à vacinação anti-rábica experimental determinada pela glucana em camundongos. Esta atividade pôde ser detectada por aumento da resistência à infecção e pela resposta imune mais intensa em termos de títulos de anticorpos. Estes resultados foram mais evidentes quando a glucana foi utilizada em doses de 0.5mg, administrada por via i.p., antes, durante e após a imunização e o desafio feito no coxim plantar da pata posterior.

Published
1993
Full Text
View/download PDF

32. Hérnia de disco torácica operada por toracoscopia videoassistida

Author

R. Zanetti O. Tella, M. Gehter, and L. H. Mattos Pimenta

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Magnification, High resolution, Fast recovery, Dissection (medical), medicine.disease, Intercostal pain, Thoracoscopy, Medicine, Radiology, business, Thoracic disc
Abstract

Os augures apresentam seus cinco primeiros casos de hérnia de disco torácica submetidos à cirurgia pela técnica de toracoscopia videoendoscópica. Descrevemos detalhadamente os passos dessa nova técnica que permite a abordagem do disco intervertebral torácico por via ânteroo-lateral e de forma minimamente invasiva. Através de pequenos orifícios de 1 5-2 em na parede torácica são introduzidos aparelhos de visão, seccão, coagulação e aspiração que possibilitam todas as manobras antes realizadas somente a céu aberto. O resultado mais importante desse trabalho foi a recuperação mais rápida do paciente (internação de 3 a 4 dias) sem necessidade de internação em terapia intensiva com retorno precoce ao trabalho. Como complicações observamos a dor torácica pós-operatória que durou 24 a 48 h em 3 pacientes não tendo ocorrido óbito nem infecção. Por se tratar de técnica minimamente invasiva e portanto com menor morbidade relacionada ao procedimento esta cirurgia pode ser indicada mais precocemente antes de instalado déficit neurológico severo.

Published
2018
Full Text
View/download PDF

34. Engano na administração de soro-vacinação para raiva. Emprego de esquema improvisado e sua avaliação: apresentação de um caso An error in administration of serum vaccination for rabies. Use and evaluation of an improvised scheme: a case report

Author

Carlos R. Zanetti, Alessandra Dellavance, João C. M. Cavallero, and Octavio A. C. Pereira

Subjects
Tratamento anti-rábico humano, Esquema improvisado, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

Apresentamos registro de caso de paciente agredida por cão que morreu 4 dias depois, e que se apresentou para tratamento 11 dias após o acidente. Foi indicado esquema de soro-vacinação a ser iniciado imediatamente com administração de soro anti-rábico (9ml, correspondente a 40 UI/Kg de peso) e série de 10 doses de vacina aplicadas em dias consecutivos e 3 doses de reforço, com 10 dias de intervalo, conforme normas da Secretaria da Saúde do Estado de São Paulo. Por engano, entretanto, foram aplicadas inicialmente 9 doses de vacina em 3 locais anatômicos diferentes. Verificado o erro de imediato, optamos pela suspensão do tratamento por alguns dias e sua reimplantação completa, o que só foi feito após 8 dias. O seguimento sorológico (pelas provas de soro-neutralização em cultura celular) evidenciou resposta inteiramente satisfatória, superando largamente em níveis, precocidade e duração as recomendações da OMS. A paciente permanecia sadia até o 240º dia após o acidente, quando foi observada pela última vez antes desta publicação.We report on a female patient attacked by a dog that died 4 days later, who sough treatment 11 days after the accident.A serum vaccination schedule was indicated, to be started immediately with the administration of anti-rabies serum (9 ml, corresponding to 40 IU/Kg body weight) and a series of 10 doses of vaccine applied on consecutive days plus 3 booster doses applied at 10-day intervals, according to the regulations of the Health . Secretariat of the State of Sao Paulo. However, due to an error, 9 vaccine doses were iniatially applied at 3 different anatomical sites. The error was immediately discovered and it was decided to interrup treatment for a few days and to restart and complete it later; this was done only 8 days later. Serologic follow-up by the serum-neutralization test in cell culture revealed a fully satisfactory response greatly exceeding WHO recommendations in terms of levels, precocity and duration. The patient continued to be healthy by the 240th day after the accident, when she was observed for the last time before this publication.

Published
1993
Full Text
View/download PDF

35. Mammographic breast density and characteristics of invasive breast cancer

Author

Greta Carioli, Stefano Rosso, Margherita Pizzato, R. Zanetti, and C. La Vecchia

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Epidemiology, Breast imaging, Breast Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, Humans, 030212 general & internal medicine, Family history, skin and connective tissue diseases, Lymph node, Aged, Breast Density, business.industry, Cancer, Odds ratio, Middle Aged, medicine.disease, Cancer registry, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, business, Body mass index
Abstract

Introduction Inconclusive data exist on the association between breast density and breast cancer characteristics. Materials and methods We conducted a case-only study on 667 invasive breast cancers, using data from the Piedmont Cancer Registry. We applied a multivariate logistic regression model to estimate odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) of high breast density (Breast Imaging Reporting and Data System, BI-RADS 3−4) versus low (BI-RADS 1−2) in relation to histologic grade, pathological tumour size and lymph node status, histotype, estrogen and progesterone receptor, HER2 and Ki67 status. Histopathological data were assessed according to the American Joint Committee on Cancer (AJCC) Staging Manual guidelines. The model includes terms for age at diagnosis, education level, body mass index, reproductive factors, family history of breast cancer, smoking and diabetes. Results As regards histologic grade, compared to well differentiated tumours, the OR of high (versus low) breast density cases was 0.61 (95% CI 0.38−0.98) for moderately-poorly differentiated tumours. No other associations with hormonal and histopathological characteristics were observed. Discussion Our results indicate that low breast density is associated with moderately-poorly differentiated breast tumours.

Published
2021
Full Text
View/download PDF

36. Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author

Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis, Tıp Fakültesi, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis

Subjects
0301 basic medicine, Universal Health Coverage, population-based registries, Relative Survival, Settore MED/42 - Igiene Generale E Applicata, Cancer -- Treatment, Humans, Neoplasms, Population Surveillance, Registries, Survival Rate, Medicine (all), 0302 clinical medicine, cancer survival, education.field_of_study, Relative survival, EPICENE, General Medicine, 3. Good health, trend, 030220 oncology & carcinogenesis, Public-Health, cancer surveillance, Liver cancer, survival, cancer registry, CONCORD-3, Cure, Childhood-Cancer, medicine.medical_specialty, population-based cancer registries, Womens Cancers, Population, Medicine (all),cancer survival, population-based cancer registries, Socio-culturale, United-States, Article, 03 medical and health sciences, Breast cancer, Cancer epidemiology, medicine, Nordic-Countries, Cancer -- Mortality, education, Survival rate, Cancer prevention, Alternative Approach, business.industry, Public health, Cancer, Cancer -- Patients -- Long-term care, medicine.disease, 030104 developmental biology, High-Income Countries, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract

Eser, Sultan (Balikesir Author), Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.Findings For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer., American Cancer Society Centers for Disease Control and Prevention Swiss Re Swiss Cancer Research foundation Swiss Cancer League Institut National du Cancer La Ligue Contre le Cancer Rossy Family Foundation US National Cancer Institute Susan G Komen Foundation

Published
2018
Full Text
View/download PDF

37. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

Author

Roberta De Angelis, Pamela Minicozzi, Milena Sant, Luigino Dal Maso, David H. Brewster, Gemma Osca-Gelis, Otto Visser, Marc Maynadié, Rafael Marcos-Gragera, Xavier Troussard, Dominic Agius, Paolo Roazzi, Elisabetta Meneghini, Alain Monnereau, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter

Subjects
Oncology, Cancer registry, Europe, Hodgkin lymphoma, Leukaemia, Lymphoma, Multiple myeloma, Non-Hodgkin lymphoma, Relative survival, Cancer Research, education.field_of_study, medicine.medical_specialty, Myeloid, business.industry, Population, Follicular lymphoma, Plasma cell neoplasm, medicine.disease, medicine.anatomical_structure, hemic and lymphatic diseases, Internal medicine, Immunology, Medicine, education, business, International Classification of Diseases for Oncology
Abstract

BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participating cancer registries from 29 European countries. Mean survival in Europe was calculated as the population weighted average of country-specific estimates. RESULTS: On average in Europe, 5-year relative survival was highest for Hodgkin lymphoma (81% ; 40, 625 cases), poorest for acute myeloid leukaemia (17% ; 57, 026 cases), and intermediate for non- Hodgkin lymphoma (59% ; 329, 204 cases), chronic myeloid leukaemia (53% ; 17, 713 cases) and plasma cell neoplasms (39% ; 94, 024 cases). Survival was generally lower in Eastern Europe and highest in Central and Northern Europe. Wider between country differences (>10%) were observed for malignancies that benefited from therapeutic advances, such as chronic myeloid leukaemia, chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma and multiple myeloma. Lower differences (

Published
2015
Full Text
View/download PDF

38. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study

Author

Otto Visser, Eva Ardanaz, Laura Botta, Milena Sant, Andrea Tavilla, Pamela Minicozzi, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Verhoeven, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, and R. Otter

Subjects
Oncology, Ependymoma, Cancer Research, medicine.medical_specialty, Pediatrics, Oligoastrocytoma, Relative survival, business.industry, Cancer, Astrocytoma, medicine.disease, Cancer registry, Internal medicine, medicine, Brain tumours, Survival, Oligodendroglioma, business, Pathological
Abstract

Background Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000–2007 in Europe. Methods For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999–2001, 2002–2004 and 2005–2007). Results Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10–12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74 years of age. Conclusions Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.

Published
2015
Full Text
View/download PDF

39. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

Author

Bernd Holleczek, Silvia Rossi, Agius Domenic, Kaire Innos, Pamela Minicozzi, Silvia Francisci, Monika Hackl, Nora Eisemann, Hermann Brenner, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, E. Crocetti, G. Manneschi, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, A. Zucchetto, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, M. Zarcone, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, P. Giorgi Rossi, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, R. Micallef, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, K. Kepska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, M. Errezola, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, L. Vilardell, M.J. Sanchez, E. Molina, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, D. Fitzpatrick, D.H. Brewster, D.W. Huws, C. White, and R. Otter

Subjects
Cancer Research, medicine.medical_specialty, education.field_of_study, Relative survival, Colorectal cancer, business.industry, Cancer registries, EUROCARE-5 study, Population-based, Population, Age at diagnosis, Cancer, Rectum, Treatment options, medicine.disease, digestive system diseases, Surgery, medicine.anatomical_structure, Oncology, Internal medicine, Cohort, medicine, business, education
Abstract

Background Previous population-based studies revealed major variation in survival for patients with colorectal cancer (CRC) in Europe by age and between different countries and regions, but also a sustained improvement in survival for patients with CRC in recent years. This EUROCARE-5 paper aims to update available knowledge from previous studies and to provide the latest survival estimates for CRC patients from Europe. Methods The study analysed data of patients diagnosed with CRC from population-based cancer registries diagnosed in 29 European countries. Estimates of 1-year and 5-year relative survival (RS) were derived for patients diagnosed in 2000–2007 by European region, country and age at diagnosis. Additionally to these cohort estimates, time trends in 5-year RS were obtained for the calendar periods 1999–2001 and 2005–2007, using the period analysis methodology. Results European average 5-year RS for patients diagnosed with colon and rectum cancer was 57% and 56%, respectively. The analyses showed persistent differences in cancer survival across Europe with lowest survival for CRC patients observed in Eastern Europe. The analyses further showed a strong gradient in age-specific survival. Even though the study revealed sustained improvement in patient survival between 1999–2001 and 2005–2007 (absolute increase of 4 and 6 percentage points for colon and rectum, respectively), the differences in the survival for CRC patients observed at the beginning of the millennium persisted over time. Conclusion Although survival for CRC patients in Europe improved markedly in the study period, significant geographic variations and a strong age gradient still persisted. Enhanced access to effective diagnostic procedures and treatment options might be the keys to reducing the existing disparities in the survival of CRC patients across Europe.

Published
2015
Full Text
View/download PDF

40. Frequent use of emergency departments: an application to the paediatric context

Author

Lucia Leporatti, W. Locatelli, R. Zanetti, Marcello Montefiori, Luca Gandullia, and E. di Bella

Subjects
business.industry, Logit, Emergency Departments, Frequent use, Emergency Departments, Risk factors, paediatric patients, Alcohol abuse, Context (language use), Overcrowding, medicine.disease, Affect (psychology), Frequent use, Clinical pathway, Risk factors, medicine, paediatric patients, Set (psychology), business, Demography, Multinomial logistic regression
Abstract

Frequent users of Emergency Departments (EDs) represent a particularly interesting category of users since they account to a small percentage of patients but they affect considerably accesses, overcrowding and the overall costs of ED activities. The literature on the topic is vast and it allows to delineate a profile of frequent users identifying socio-demographic (age, gender, nationality) and clinical (chronic diseases, drugs and alcohol abuse; psychic illnesses) risk factors. However, most of the studies on the topic limit the analysis to one-year period or to a single study site and there is no consensus on the definition of frequent use. Frequent users are generally defined as those patients reporting a number of accesses per year beyond a certain threshold. The selection of the threshold is often based on previous literature or on percentiles but the definitions vary considerably and the choice tends to be subjective.In this study, the focus will be placed on paediatric patients, with reference to which the contributions in the literature are still very limited. The objective is to identify the most important drivers of ED frequent use in the 19 EDs of Liguria region (Italy) during a three-year period (2013-2015). The dataset contains 287,242 accesses referred to 144,895 under 14 patients and it includes information on patients? characteristics and on their clinical pathway. To overcome the limitations connected to previous definitions of frequent use, we exploit the availability of data on three years; this allows to define, not only frequent use, but also its duration (i.e. One-shot / Multiple shot frequent use) and intensity (Normal, High, Very high). By the use of logit and multinomial logit regressions we identify a set of risk factors associated to frequent use and to the different forms of frequent use. Results show that even if frequent users represent a small share of patients (9%) they contribute to roughly 25% of accesses. Chronic conditions are the most relevant determinants of frequent use (particularly mental disorders, diseases of the respiratory system) but also foreign nationality turns out to be an important predictor. Differences emerge in the impact of regressors on the different forms of frequent use defined according to its duration and intensity.The study represents an important tool to support policy-making and to discriminate between the potentially preventable frequent use (i.e. inappropriate use) and that associated to complex medical conditions, such as chronic conditions.

Published
2018

41. Bose-Einstein correlations in pp, pPb, and PbPb collisions at root s(NN)=0.9-7 TeV

Author

Sirunyan, A. M. Tumasyan, A. Adam, W. Ambrogi, F. and Asilar, E. Bergauer, T. Brandstetter, J. Brondolin, E. and Dragicevic, M. Eroe, J. Flechl, M. Friedl, M. and Fruehwirth, R. Ghete, V. M. Grossmann, J. Hrubec, J. and Jeitler, M. Koenig, A. Krammer, N. Kraetschmer, I Liko, D. Madlener, T. Mikulec, I Pree, E. Rabady, D. Rad, N. Rohringer, H. Schieck, J. Schoefbeck, R. Spanring, M. and Spitzbart, D. Strauss, J. Waltenberger, W. Wittmann, J. and Wulz, C-E Zarucki, M. Chekhovsky, V Mossolov, V and Gonzalez, J. Suarez De Wolf, E. A. Di Croce, D. Janssen, X. and Lauwers, J. Van De Klundert, M. Van Haevermaet, H. Van Mecheleny, P. Van Remortel, N. Abu Zeid, S. Blekman, F. and D'Hondt, J. De Bruyn, I De Clercq, J. Deroover, K. and Flouris, G. Lontkovskyi, D. Lowette, S. Moortgat, S. and Moreels, L. Olbrechts, A. Python, Q. Skovpen, K. and Tavernier, S. Van Doninck, W. Van Mulders, P. Van Parijs, I and Brun, H. Clerbaux, B. De Lentdecker, G. Delannoy, H. and Fasanella, G. Favart, L. Goldouzian, R. Grebenyuk, A. and Karapostoli, G. Lenzi, T. Luetic, J. Maerschalk, T. and Marinov, A. Randle-Conde, A. Seva, T. Vander Velde, C. and Vanlaer, P. Vannerom, D. Yonamine, R. Zenoni, F. Zhang, F. Cimmino, A. Cornelis, T. Dobur, D. Fagot, A. Gul, M. Khvastunov, I Poyraz, D. Roskas, C. Salva, S. and Tytgat, M. Verbeke, W. Zaganidis, N. Bakhshiansohi, H. and Bondu, O. Brochet, S. Bruno, G. Caudron, A. De Visscher, S. Delaere, C. Delcourt, M. Francois, B. Giammanco, A. and Jafari, A. Komm, M. Krintiras, G. Lemaitre, V and Magitteri, A. Mertens, A. Musich, M. Piotrzkowski, K. and Quertenmont, L. Marono, M. Vidal Wertz, S. Beliy, N. and Alda Junior, W. L. Alves, F. L. Alves, G. A. Brito, L. and Correa Martins Junior, M. Hensel, C. Moraes, A. Pol, M. E. and Rebello Teles, P. Belchior Batista Das Chagas, E. Carvalho, W. Chinellato, J. Custodio, A. Da Costa, E. M. Da Silveira, G. G. De Jesus Damiao, D. Fonseca De Souza, S. and Huertas Guativa, L. M. Malbouisson, H. Melo De Almeida, M. and Mora Herrera, C. Mundim, L. Nogima, H. Santoro, A. and Sznajder, A. Tonelli Manganote, E. J. Torres Da Silva De Araujo, F. Vilela Pereira, A. Ahuja, S. Bernardes, C. A. Dogra, S. Fernandez Perez Tomei, T. R. Gregores, E. M. Mercadante, P. G. Novaes, S. F. Padula, Sandra S. Romero Abad, D. and Ruiz Vargas, J. C. Aleksandrov, A. Hadjiiska, R. Iaydjiev, P. Misheva, M. Rodozov, M. Shopova, M. Stoykova, S. and Sultanov, G. Dimitrov, A. Glushkov, I Litov, L. Pavlov, B. Petkov, P. Fang, W. Gao, X. Ahmad, M. Bian, J. G. and Chen, G. M. Chen, H. S. Chen, M. Chen, Y. Jiang, C. H. Leggat, D. Liao, H. Liu, Z. Romeo, F. Shaheen, S. M. Spiezia, A. Tao, J. Wang, C. Wang, Z. Yazgan, E. and Zhang, H. Zhao, J. Ban, Y. Chen, G. Li, Q. Liu, S. Mao, Y. Qian, S. J. Wang, D. Xu, Z. Avila, C. and Cabrera, A. Carrillo Montoya, C. A. Chaparro Sierra, L. F. and Florez, C. Gonzalez Hernandez, C. F. Ruiz Alvarez, J. D. and Courbon, B. Godinovic, N. Lelas, D. Puljak, I Ribeiro Cipriano, P. M. Sculac, T. Antunovic, Z. Kovac, M. and Brigljevic, V Ferencek, D. Kadija, K. Mesic, B. and Starodumov, A. Susa, T. Ather, M. W. Attikis, A. and Mavromanolakis, G. Mousa, J. Nicolaou, C. Ptochos, F. and Razis, P. A. Rykaczewski, H. Finger, M. Carrera Jarrin, E. and Assran, Y. Mahmoud, M. A. Mahrous, A. Dewanjee, R. K. and Kadastik, M. Perrini, L. Raidal, M. Tiko, A. and Veelken, C. Eerola, P. Pekkanen, J. Voutilainen, M. and Harkonen, J. Jarvinen, T. Karimaki, V Kinnunen, R. and Lampen, T. Lassila-Perini, K. Lehti, S. Linden, T. and Luukka, P. Tuominen, E. Tuominiemi, J. Tuovinen, E. and Talvitie, J. Tuuva, T. Besancon, M. Couderc, F. and Dejardin, M. Denegri, D. Faure, J. L. Ferri, F. Ganjour, S. Ghosh, S. Givernaud, A. Gras, P. de Monchenault, G. Hamel Jarry, P. Kucher, I Locci, E. Machet, M. and Malcles, J. Negro, G. Rander, J. Rosowsky, A. Sahin, M. O. Titov, M. Abdulsalam, A. Antropov, I Baffioni, S. and Beaudette, F. Busson, P. Cadamuro, L. Charlot, C. de Cassagnac, R. Granier Jo, M. Lisniak, S. Lobanov, A. and Blanco, J. Martin Nguyen, M. Ochando, C. Ortona, G. and Paganini, P. Pigard, P. Regnard, S. Salerno, R. Sauvan, J. B. Sirois, Y. Leiton, A. G. Stahl Strebler, T. and Yilmaz, Y. Zabi, A. Zghiche, A. Agram, J-L Andrea, J. and Bloch, D. Brom, J-M Buttignol, M. Chabert, E. C. and Chanon, N. Collard, C. Conte, E. Coubez, X. Fontaine, J-C Gele, D. Goerlach, U. Jansova, M. Le Bihan, A-C and Tonon, N. Van Hove, P. Gadrat, S. Beauceron, S. Bernet, C. Boudoul, G. Chierici, R. Contardo, D. Depasse, P. and El Mamouni, H. Fay, J. Finco, L. Gascon, S. Gouzevitch, M. Grenier, G. Ille, B. Lagarde, F. Laktineh, I. B. and Lethuillier, M. Mirabito, L. Pequegnot, A. L. Perries, S. and Popov, A. Sordini, V Vander Donckt, M. Viret, S. and Toriashvili, T. Tsamalaidze, Z. Autermann, C. Beranek, S. and Feld, L. Kiesel, M. K. Klein, K. Lipinski, M. and Preuten, M. Schomakers, C. Schulz, J. Verlage, T. and Albert, A. Dietz-Laursonn, E. Duchardt, D. Endres, M. and Erdmann, M. Erdweg, S. Esch, T. Fischer, R. Gueth, A. and Hamer, M. Hebbeker, T. Heidemann, C. Hoepfner, K. and Knutzen, S. Merschmeyer, M. Meyer, A. Millet, P. and Mukherjee, S. Olschewski, M. Padeken, K. Pook, T. and Radziej, M. Reithler, H. Rieger, M. Scheuch, F. and Teyssier, D. Thueer, S. Fluegge, G. Kargoll, B. Kress, T. Kuensken, A. Lingemann, J. Mueller, T. Nehrkorn, A. and Nowack, A. Pistone, C. Pooth, O. Stahl, A. Martin, M. Aldaya Arndt, T. Asawatangtrakuldee, C. Beernaert, K. and Behnke, O. Behrens, U. Martinez, A. Bermudez Bin Anuar, A. A. Borras, K. Botta, V Campbell, A. Connor, P. and Contreras-Campana, C. Costanza, F. Pardos, C. Diez Eckerlin, G. Eckstein, D. Eichhorn, T. Eren, E. Gallo, E. and Garcia, J. Garay Geiser, A. Gizhko, A. Luyando, J. M. Grados and Grohsjean, A. Gunnellini, P. Harb, A. Hauk, J. and Hempel, M. Jung, H. Kalogeropoulos, A. Kasemann, M. and Keaveney, J. Kleinwort, C. Korol, I Kruecker, D. Lange, W. Lelek, A. Lenz, T. Leonard, J. Lipka, K. Lohmann, W. Mankel, R. Melzer-Pellmann, I-A Meyer, A. B. Mittag, G. Mnich, J. Mussgiller, A. Ntomari, E. Pitzl, D. and Placakyte, R. Raspereza, A. Roland, B. Savitskyi, M. and Saxena, P. Shevchenko, R. Spannagel, S. Stefaniuk, N. and Van Onsem, G. P. Walsh, R. Wen, Y. Wichmann, K. Wissing, C. Zenaiev, O. Bein, S. Blobel, V Vignali, M. Centis and Dreyer, T. Garutti, E. Gonzalez, D. Haller, J. Hinzmann, A. Hoffmann, M. Karavdina, A. Klanner, R. Kogler, R. and Kovalchuk, N. Kurz, S. Lapsien, T. Marchesini, I and Marconi, D. Meyer, M. Niedziela, M. Nowatschin, D. and Pantaleo, F. Peiffer, T. Perieanu, A. Scharf, C. and Schleper, P. Schmidt, A. Schumann, S. Schwandt, J. and Sonneveld, J. Stadie, H. Steinbrueck, G. Stober, F. M. and Stoever, M. Tholen, H. Troendle, D. Usai, E. Vanelderen, L. Vanhoefer, A. Vormwald, B. Akbiyik, M. Barth, C. and Baur, S. Butz, E. Caspart, R. Chwalek, T. Colombo, F. and De Boer, W. Dierlamm, A. Freund, B. Friese, R. and Giffels, M. Gilbert, A. Haitz, D. Hartmann, F. Heindl, S. M. Husemann, U. Kassel, F. Kudella, S. Mildner, H. and Mozer, M. U. Mueller, Th Plagge, M. Quast, G. and Rabbertz, K. Schroeder, M. Shvetsov, I Sieber, G. and Simonis, H. J. Ulrich, R. Wayand, S. Weber, M. Weiler, T. Williamson, S. Woehrmann, C. Wolf, R. Anagnostou, G. and Daskalakis, G. Geralis, T. Giakoumopoulou, V. A. and Kyriakis, A. Loukas, D. Topsis-Giotis, I Kesisoglou, S. and Panagiotou, A. Saoulidou, N. Evangelou, I Foudas, C. and Kokkas, P. Mallios, S. Manthos, N. Papadopoulos, I and Paradas, E. Strologas, J. Triantis, F. A. Csanad, M. and Filipovic, N. Pasztor, G. Bencze, G. Hajdu, C. Horvath, D. Hunyadi, A. Sikler, F. Veszpremi, V. Vesztergombi, G. and Zsigmond, A. J. Beni, N. Czellar, S. Karancsi, J. and Makovec, A. Molnar, J. Szillasi, Z. Bartok, M. Raics, P. and Trocsanyi, Z. L. Ujvari, B. Choudhury, S. Komaragiri, J. R. Bahinipati, S. Bhowmik, S. Mal, P. Mandal, K. and Nayak, A. Sahoo, D. K. Sahoo, N. Swain, S. K. Bansal, S. and Beri, S. B. Bhatnagar, V Bhawandeep, U. Chawla, R. and Dhingra, N. Kalsi, A. K. Kaur, A. Kaur, M. Kumar, R. and Kumari, P. Mehta, A. Singh, J. B. Walia, G. Kumar, Ashok and Shah, Aashaq Bhardwaj, A. Chauhan, S. Choudhary, B. C. and Garg, R. B. Keshri, S. Kumar, A. Malhotra, S. and Naimuddin, M. Ranjan, K. Sharma, R. Sharma, V Bhardwaj, R. Bhattacharya, R. Bhattacharya, S. Dey, S. Dutt, S. and Dutta, S. Majumdar, N. Modak, A. Mondal, K. and Mukhopadhyay, S. Nandan, S. Purohit, A. Roy, A. Roy, D. and Chowdhury, S. Roy Sarkar, S. Sharan, M. Thakur, S. and Behera, P. K. Chudasama, R. Dutta, D. Jha, V Kumar, V and Mohanty, A. K. Netrakanti, P. K. Pant, L. M. Shukla, P. and Topkar, A. Aziz, T. Dugad, S. Mahakud, B. Mitra, S. and Mohanty, G. B. Sur, N. Sutar, B. Banerjee, S. and Chatterjee, S. Das, P. Guchait, M. Jain, Sa Kumar, S. and Maity, M. Majumder, G. Mazumdar, K. Sarkar, T. and Wickramage, N. Dube, S. Hegde, V Kapoor, A. Kothekar, K. and Pandey, S. Rane, A. Sharma, S. Chenarani, S. and Tadavani, E. Eskandari Etesami, S. M. Khakzad, M. and Najafabadi, M. Mohammadi Naseri, M. Mehdiabadi, S. Paktinat and Hosseinabadi, F. Rezaei Safarzadeh, B. Zeinali, M. Felcini, M. Grunewald, M. Abbrescia, M. Calabria, C. Caputo, C. and Colaleo, A. Creanza, D. Cristella, L. De Filippis, N. and De Palma, M. Errico, F. Fiore, L. Iaselli, G. Lezki, S. Maggi, G. Maggi, M. Miniello, G. My, S. Nuzzo, S. and Pompili, A. Pugliese, G. Radogna, R. Ranieri, A. and Selvaggi, G. Sharma, A. Silvestris, L. Venditti, R. and Verwilligen, P. Abbiendi, G. Battilana, C. Bonacorsi, D. and Braibant-Giacomelli, S. Campanini, R. Capiluppi, P. Castro, A. Cavallo, F. R. Chhibra, S. S. Codispoti, G. Cuffiani, M. Dallavalle, G. M. Fabbri, F. Fanfani, A. Fasanella, D. Giacomelli, P. Grandi, C. Guiducci, L. Marcellini, S. and Masetti, G. Montanari, A. Navarria, F. L. Perrotta, A. and Rossi, A. M. Rovelli, T. Siroli, G. P. Tosi, N. and Albergo, S. Costa, S. Di Mattia, A. Giordano, F. and Potenza, R. Tricomi, A. Tuve, C. Barbagli, G. and Chatterjee, K. Ciulli, V Civinini, C. D'Alessandro, R. and Focardi, E. Lenzi, P. Meschini, M. Paoletti, S. Russo, L. Sguazzoni, G. Strom, D. Viliani, L. Benussi, L. and Bianco, S. Piccolo, D. Primavera, F. Calvelli, V Ferro, F. Robutti, E. Tosi, S. Brianza, L. Brivio, F. and Ciriolo, V Dinardo, M. E. Fiorendi, S. Gennai, S. and Ghezzi, A. Govoni, P. Malberti, M. Malvezzi, S. Manzoni, R. A. Menasce, D. Moroni, L. Paganoni, M. Pauwels, K. and Pedrini, D. Pigazzini, S. Ragazzi, S. de Fatis, T. Tabarelli Buontempo, S. Cavallo, N. Di Guida, S. and Fabozzi, F. Fienga, F. Iorio, A. O. M. Khan, W. A. and Lista, L. Meola, S. Paolucci, P. Sciacca, C. Thyssen, F. and Azzi, P. Bacchetta, N. Benato, L. Bisello, D. and Boletti, A. Carlin, R. De Oliveira, A. Carvalho Antunes and Checchia, P. Manzano, P. De Castro Dorigo, T. Dosselli, U. and Gasparini, F. Gasparini, U. Gonella, F. Gozzelino, A. and Gulmini, M. Lacaprara, S. Lujan, P. Margoni, M. and Pozzobon, N. Ronchese, P. Rossin, R. Zanetti, M. Zotto, P. Zumerle, G. Braghieri, A. Fallavollita, F. Magnani, A. Montagna, P. Ratti, S. P. Re, V Ressegotti, M. and Riccardi, C. Salvini, P. Vai, I Vitulo, P. Solestizi, L. Alunni Biasini, M. Bilei, G. M. Cecchi, C. Ciangottini, D. Fano, L. Lariccia, P. Leonardi, R. Manoni, E. and Mantovani, G. Mariani, V Menichelli, M. Rossi, A. and Santocchia, A. Spiga, D. Androsov, K. Azzurri, P. and Bagliesi, G. Bernardini, J. Boccali, T. Borrello, L. and Castaldi, R. Ciocci, M. A. Dell'Orso, R. Fedi, G. and Giannini, L. Giassi, A. Grippo, M. T. Ligabue, F. and Lomtadze, T. Manca, E. Mandorli, G. Martini, L. and Messineo, A. Palla, F. Rizzi, A. Savoy-Navarro, A. and Spagnolo, P. Tenchini, R. Tonelli, G. Venturi, A. and Verdini, P. G. Barone, L. Cavallari, F. Cipriani, M. and Daci, N. Del Re, D. Diemoz, M. Gelli, S. Longo, E. and Margaroli, F. Marzocchi, B. Meridiani, P. Organtini, G. and Paramatti, R. Preiato, F. Rahatlou, S. Rovelli, C. and Santanastasio, F. Amapane, N. Arcidiacono, R. Argiro, S. and Arneodo, M. Bartosik, N. Bellan, R. Biino, C. Cartiglia, N. Cenna, F. Costa, M. Covarelli, R. Degano, A. and Demaria, N. Kiani, B. Mariotti, C. Maselli, S. Migliore, E. Monaco, V Monteil, E. Monteno, M. Obertino, M. M. and Pacher, L. Pastrone, N. Pelliccioni, M. Angioni, G. L. Pinna and Ravera, F. Romero, A. Ruspa, M. Sacchi, R. and Shchelina, K. Sola, V Solano, A. Staiano, A. Traczyk, P. and Belforte, S. Casarsa, M. Cossutti, F. Della Ricca, G. and Zanetti, A. Kim, D. H. Kim, G. N. Kim, M. S. Lee, J. and Lee, S. Lee, S. W. Moon, C. S. Oh, Y. D. Sekmen, S. and Son, D. C. Yang, Y. C. Lee, A. Kim, H. Moon, D. H. and Oh, G. Cifuentes, J. A. Brochero Goh, J. Kim, T. J. and Cho, S. Choi, S. Go, Y. Gyun, D. Ha, S. Hong, B. and Jo, Y. Kim, Y. Lee, K. Lee, K. S. Lim, J. Park, S. K. Roh, Y. Almond, J. Kim, J. Kim, J. S. Lee, H. and Nam, K. Oh, S. B. Radburn-Smith, B. C. Seo, S. H. Yang, U. K. Yoo, H. D. Yu, G. B. Choi, M. Kim, J. H. Lee, J. S. H. Park, I. C. Ryu, G. Choi, Y. Hwang, C. Yu, I Dudenas, V Juodagalvis, A. Vaitkus, J. Ahmed, I and Ibrahim, Z. A. Ali, M. A. B. Md Idris, F. Mohamad Abdullah, W. A. T. Wan Yusli, M. N. Zolkapli, Z. Duran-Osuna, M. C. and Castilla-Valdez, H. De La Cruz-Burelo, E. Heredia-De La Cruz, I Lopez-Fernandez, R. Mejia Guisao, J. Rabadan-Trejo, I, R. Ramirez-Sanchez, G. Reyes-Almanza, R. and Sanchez-Hernandez, A. Carrillo Moreno, S. Oropeza Barrera, C. and Vazquez Valencia, F. Pedraza, I Salazar Ibarguen, H. A. and Uribe Estrada, C. Morelos Pineda, A. Krofcheck, D. Butler, P. H. Ahmad, A. Hassan, Q. Hoorani, H. R. Saddique, A. and Shah, M. A. Shoaib, M. Waqas, M. Bialkowska, H. and Bluj, M. Boimska, B. Frueboes, T. Gorski, M. Kazana, M. and Nawrocki, K. Romanowska-Rybinska, K. Szleper, M. and Zalewski, P. Bunkowski, K. Byszuk, A. Doroba, K. and Kalinowski, A. Konecki, M. Krolikowski, J. Misiura, M. and Olszewski, M. Pyskir, A. Walczak, M. Bargassa, P. Beirao Da Cruz E Silva, C. Calpas, B. Di Francesco, A. Faccioli, P. and Gallinaro, M. Hollar, J. Leonardo, N. Lloret Iglesias, L. Nemallapudi, V, M. Seixas, J. Toldaiev, O. Vadruccio, D. Varela, J. Afanasiev, S. Bunin, P. Gavrilenko, M. and Golutvin, I Gorbunov, I Kamenev, A. Karjavin, V Lanev, A. Malakhov, A. Matveev, V Palichik, V Perelygin, V and Shmatov, S. Shulha, S. Skatchkov, N. Smirnov, V and Voytishin, N. Zarubin, A. Ivanov, Y. Kim, V Kuznetsova, E. Levchenko, P. Murzin, V Oreshkin, V Smirnov, I and Sulimov, V Uvarov, L. Vavilov, S. Vorobyev, A. Andreev, Yu Dermenev, A. Gninenko, S. Golubev, N. Karneyeu, A. and Kirsanov, M. Krasnikov, N. Pashenkov, A. Tlisov, D. and Toropin, A. Epshteyn, V Gavrilov, V Lychkovskaya, N. and Popov, V Pozdnyakov, I Safronov, G. Spiridonov, A. and Stepennov, A. Toms, M. Vlasov, E. Zhokin, A. Aushev, T. and Bylinkin, A. Andreev, V Azarkin, M. Dremin, I and Kirakosyan, M. Terkulov, A. Baskakov, A. Belyaev, A. and Boos, E. Ershov, A. Gribushin, A. Khein, L. Klyukhin, V and Kodolova, O. Lokhtin, I Lukina, O. Miagkov, I and Obraztsov, S. Petrushanko, S. Savrin, V Snigirev, A. and Blinov, V Shtol, D. Skovpen, Y. Azhgirey, I Bayshev, I and Bitioukov, S. Elumakhov, D. Kachanov, V Kalinin, A. and Konstantinov, D. Krychkine, V Petrov, V Ryutin, R. and Sobol, A. Troshin, S. Tyurin, N. Uzunian, A. Volkov, A. and Adzic, P. Cirkovic, P. Devetak, D. Dordevic, M. and Milosevic, J. Rekovic, V Alcaraz Maestre, J. Barrio Luna, M. and Cerrada, M. Colino, N. De La Cruz, B. Delgado Peris, A. and Escalante Del Valle, A. Fernandez Bedoya, C. Fernandez Ramos, J. P. Flix, J. Fouz, M. C. Garcia-Abia, P. and Gonzalez Lopez, O. Goy Lopez, S. Hernandez, J. M. Josa, I, M. Perez-Calero Yzquierdo, A. Puerta Pelayo, J. Quintario Olmeda, A. Redondo, I Romero, L. Soares, M. S. Alvarez Fernandez, A. Albajar, C. de Troconiz, J. F. Missiroli, M. and Moran, D. Cuevas, J. Erice, C. Fernandez Menendez, J. and Gonzalez Caballero, I Gonzalez Fernandez, J. R. Palencia Cortezon, E. Sanchez Cruz, S. Suarez Andres, I Vischia, P. and Vizan Garcia, J. M. Cabrillo, I. J. Calderon, A. Chazin Quero, B. Curras, E. Fernandez, M. Garcia-Ferrero, J. and Gomez, G. Lopez Virto, A. Marco, J. Martinez Rivero, C. and Ruiz del Arbol, P. Martinez Matorras, F. Piedra Gomez, J. and Rodrigo, T. Ruiz-Jimeno, A. Scodellaro, L. Trevisani, N. and Vila, I Vilar Cortabitarte, R. Abbaneo, D. Auffray, E. and Baillon, P. Ball, A. H. Barney, D. Bianco, M. Bloch, P. and Bocci, A. Botta, C. Camporesi, T. Castello, R. and Cepeda, M. Cerminara, G. Chapon, E. d'Enterria, D. and Dabrowski, A. Daponte, V David, A. De Gruttola, M. De Roeck, A. Di Marco, E. Dobson, M. Dorney, B. du Pree, T. and Duenser, M. Dupont, N. Elliott-Peisert, A. Everaerts, P. and Franzoni, G. Fulcher, J. Funk, W. Gigi, D. Gill, K. and Glege, F. Gulhan, D. Gundacker, S. Guthoff, M. and Harris, P. Hegeman, J. Innocente, V Janot, P. and Karacheban, O. Kieseler, J. Kirschenmann, H. Knuenz, V and Kornmayer, A. Kortelainen, M. J. Krammer, M. Lange, C. and Lecoq, P. Lourenco, C. Lucchini, M. T. Malgeri, L. and Mannelli, M. Martelli, A. Meijers, F. Merlin, J. A. and Mersi, S. Meschi, E. Milenovic, P. Moortgat, F. Mulders, M. Neugebauer, H. Orfanelli, S. Orsini, L. Pape, L. and Perez, E. Peruzzi, M. Petrilli, A. Petrucciani, G. and Pfeiffer, A. Pierini, M. Racz, A. Reis, T. Rolandi, G. and Rovere, M. Sakulin, H. Schaefer, C. Schwick, C. and Seidel, M. Selvaggi, M. Silva, P. Sphicas, P. and Steggemann, J. Stoye, M. Tosi, M. Treille, D. Triossi, A. Tsirou, A. Veckalns, V. Veres, I, G. Verweij, M. and Wardle, N. Zeuner, W. D. Bertl, W. Caminada, L. Deiters, K. Erdmann, W. Horisberger, R. Ingram, Q. Kaestli, H. C. and Kotlinski, D. Langenegger, U. Rohe, T. Wiederkehr, S. A. and Bachmair, F. Baeni, L. Berger, P. Bianchini, L. and Casal, B. Dissertori, G. Dittmar, M. Donega, M. Grab, C. and Heidegger, C. Hits, D. Hoss, J. Kasieczka, G. and Klijnsma, T. Lustermann, W. Mangano, B. Marionneau, M. and Meinhard, M. T. Meister, D. Micheli, F. Musella, P. and Nessi-Tedaldi, F. Pandolfi, F. Pata, J. Pauss, F. and Perrin, G. Perrozzi, L. Quittnat, M. Schoenenberger, M. and Shchutska, L. Tavolaro, V. R. Theofilatos, K. Olsson, M. L. Vesterbacka Wallny, R. Zagozdzinska, A. Zhu, D. H. and Aarrestad, T. K. Amsler, C. Canelli, M. F. De Cosa, A. and Del Burgo, R. Donato, S. Galloni, C. Hreus, T. and Kilminster, B. Ngadiuba, J. Pinna, D. Rauco, G. Robmann, P. Salerno, D. Seitz, C. Takahashi, Y. Zucchetta, A. and Candelise, V Doan, T. H. Jain, Sh Khurana, R. Kuo, C. M. and Lin, W. Pozdnyakov, A. Yu, S. S. Kumar, Arun Chang, P. Chao, Y. Chen, K. F. Chen, P. H. Fiori, F. Hou, W-S Hsiung, Y. Liu, Y. F. Lu, R-S Moya, M. Minano and Paganis, E. Psallidas, A. Tsai, J. F. Asavapibhop, B. and Kovitanggoon, K. Singh, G. Srimanobhas, N. Adiguzel, A. and Boran, F. Cerci, S. Damarseckin, S. Demiroglu, Z. S. and Dozen, C. Dumanoglu, I Girgis, S. Gokbulut, G. Guler, Y. and Hos, I Kangal, E. E. Kara, O. Topaksu, A. Kayis and Kiminsu, U. Oglakci, M. Onengut, G. Ozdemir, K. Cerci, D. Sunar Tali, B. Turkcapar, S. Zorbakir, I. S. and Zorbilmez, C. Bilin, B. Karapinar, G. Ocalan, K. Yalvac, M. Zeyrek, M. Gulmez, E. Kaya, M. Kaya, O. Tekten, S. Yetkin, E. A. Agaras, M. N. Atay, S. Cakir, A. and Cankocak, K. Grynyov, B. Levchuk, L. Sorokin, P. and Aggleton, R. Ball, F. Beck, L. Brooke, J. J. Burns, D. and Clement, E. Cussans, D. Davignon, O. Flacher, H. and Goldstein, J. Grimes, M. Heath, G. P. Heath, H. F. and Jacob, J. Kreczko, L. Lucas, C. Newbold, D. M. and Paramesvaran, S. Poll, A. Sakuma, T. El Nasr-Storey, S. Seif and Smith, D. Smith, V. J. Bell, K. W. Brew, C. Brown, R. M. Calligaris, L. Cieri, D. Cockerill, D. J. A. and Coughlan, J. A. Harder, K. Harper, S. Olaiya, E. Petyt, D. Shepherd-Themistocleous, C. H. Thea, A. Tomalin, I. R. and Williams, T. Bainbridge, R. Breeze, S. Buchmuller, O. and Bundock, A. Casasso, S. Citron, M. Colling, D. and Corpe, L. Dauncey, P. Davies, G. De Wit, A. Della Negra, M. Di Maria, R. Elwood, A. Haddad, Y. Hall, G. Iles, G. James, T. Lane, R. Laner, C. Lyons, L. Magnan, A-M Malik, S. Mastrolorenzo, L. Matsushita, T. Nash, J. and Nikitenko, A. Palladino, V Pesaresi, M. Raymond, D. M. and Richards, A. Rose, A. Scott, E. Seez, C. and Shtipliyski, A. Summers, S. Tapper, A. Uchida, K. and Acosta, M. Vazquez Virdee, T. Winterbottom, D. Wright, J. and Zenz, S. C. Cole, J. E. Hobson, P. R. Khan, A. and Kyberd, P. Reid, I. D. Symonds, P. Teodorescu, L. and Turner, M. Borzou, A. Call, K. Dittmann, J. Hatakeyama, K. Liu, H. Pastika, N. Smith, C. Bartek, R. and Dominguez, A. Buccilli, A. Cooper, I, S. Henderson, C. and Rumerio, P. West, C. Arcaro, D. Avetisyan, A. Bose, T. and Gastler, D. Rankin, D. Richardson, C. Rohlf, J. and Sulak, L. Zou, D. Benelli, G. Cutts, D. Garabedian, A. and Hakala, J. Heintz, U. Hogan, J. M. Kwok, K. H. M. and Laird, E. Landsberg, G. Mao, Z. Narain, M. Pazzini, J. and Piperov, S. Sagir, S. Syarif, R. Yu, D. Band, R. and Brainerd, C. Breedon, R. Sanchez, M. Calderon De La Barca and Chertok, M. Conway, J. Conway, R. Cox, P. T. Erbacher, R. Flores, C. Funk, G. Gardner, M. Ko, W. Lander, R. and Mclean, C. Mulhearn, M. Pellett, D. Pilot, J. and Shalhout, S. Shi, M. Smith, J. Squires, M. Stolp, D. and Tos, K. Tripathi, M. Bachtis, M. Bravo, C. Cousins, R. and Dasgupta, A. Florent, A. Hauser, J. Ignatenko, M. and Mccoll, N. Saltzberg, D. Schnaible, C. Valuev, V. and Bouvier, E. Burt, K. Clare, R. Ellison, J. Gary, J. W. and Shirazi, S. M. A. Ghiasi Hanson, G. Heilman, J. Jandir, P. Kennedy, E. Lacroix, F. Long, O. R. Negrete, M. Olmedo Paneva, I, M. Shrinivas, A. Si, W. Wang, L. and Wei, H. Wimpenny, S. Yates, B. R. Branson, J. G. and Cittolin, S. Derdzinski, M. Gerosa, R. Hashemi, B. and Holzner, A. Klein, D. Kole, G. Krutelyov, V Letts, J. and Macneill, I Masciovecchio, M. Olivito, D. Padhi, S. and Pieri, M. Sani, M. Simon, S. Tadel, M. Vartak, A. and Wasserbaech, S. Wood, J. Wurthwein, F. Yagil, A. Della Porta, G. Zevi Amin, N. Bhandari, R. Bradmiller-Feld, J. and Campagnari, C. Dishaw, A. Dutta, V Sevilla, M. Franco and George, C. Golf, F. Gouskos, L. Gran, J. Heller, R. and Incandela, J. Mullin, S. D. Ovcharova, A. Qu, H. and Richman, J. Stuart, D. Suarez, I Yoo, J. Anderson, D. and Bendavid, J. Bornheim, A. Lawhorn, J. M. Newman, H. B. and Nguyen, T. Pena, C. Spiropulu, M. Vlimant, J. R. and Xie, S. Zhang, Z. Zhu, R. Y. Andrews, M. B. Ferguson, T. and Mudholkar, T. Paulini, M. Russ, J. Sun, M. Vogel, H. and Vorobiev, I Weinberg, M. Cumalat, J. P. Ford, W. T. and Jensen, F. Johnson, A. Krohn, M. Leontsinis, S. and Mulholland, T. Stenson, K. Wagner, S. R. Alexander, J. and Chaves, J. Chu, J. Dittmer, S. Mcdermott, K. Mirman, N. and Patterson, J. R. Rinkevicius, A. Ryd, A. Skinnari, L. and Soffi, L. Tan, S. M. Tao, Z. Thom, J. Tucker, J. and Wittich, P. Zientek, M. Abdullin, S. Albrow, M. and Apollinari, G. Apresyan, A. Apyan, A. Bauerdick, L. A. T. and Beretvas, A. Berryhill, J. Bhat, P. C. Bolla, G. and Burkett, K. Butler, J. N. Canepa, A. Cerati, G. B. and Cheung, H. W. K. Chlebana, F. Cremonesi, M. Duarte, J. and Elvira, V. D. Freeman, J. Gecse, Z. Gottschalk, E. Gray, L. Green, D. Grunendahl, S. Gutsche, O. Harris, R. M. and Hasegawa, S. Hirschauer, J. Hu, Z. Jayatilaka, B. and Jindariani, S. Johnson, M. Joshi, U. Klima, B. Kreis, B. and Lammel, S. Lincoln, D. Lipton, R. Liu, M. Liu, T. and De Sa, R. Lopes Lykken, J. Maeshima, K. Magini, N. and Marraffino, J. M. Maruyama, S. Mason, D. McBride, P. and Merkel, P. Mrenna, S. Nahn, S. O'Dell, V Pedro, K. and Prokofyev, O. Rakness, G. Ristori, L. Schneider, B. and Sexton-Kennedy, E. Soha, A. Spalding, W. J. Spiegel, L. and Stoynev, S. Strait, J. Strobbe, N. Taylor, L. Tkaczyk, S. Tran, V, N. Uplegger, L. Vaandering, E. W. Vernieri, C. Verzocchi, M. Vidal, R. Wang, M. Weber, H. A. and Whitbeck, A. Acosta, D. Avery, P. Bortignon, P. and Bourilkov, D. Brinkerhoff, A. Carnes, A. Carver, M. and Curry, D. Das, S. Field, R. D. Furic, I. K. Konigsberg, J. Korytov, A. Kotov, K. Ma, P. Matchev, K. Mei, H. and Mitselmakher, G. Rank, D. Sperka, D. Terentyev, N. and Thomas, L. Wang, J. Wang, S. Yelton, J. Joshi, Y. R. and Linn, S. Markowitz, P. Rodriguez, J. L. Ackert, A. and Adams, T. Askew, A. Hagopian, S. Hagopian, V Johnson, K. F. Kolberg, T. Martinez, G. Perry, T. Prosper, H. and Saha, A. Santra, A. Yohay, R. Baarmand, M. M. Bhopatkar, V Colafranceschi, S. Hohlmann, M. Noonan, D. Roy, T. and Yumiceva, F. Adams, M. R. Apanasevich, L. Berry, D. and Betts, R. R. Cavanaugh, R. Chen, X. Evdokimov, O. and Gerber, C. E. Hangal, D. A. Hofman, D. J. Jung, K. and Kamin, J. Gonzalez, I. D. Sandoval Tonjes, M. B. Trauger, H. and Varelas, N. Wang, H. Wu, Z. Zhang, J. Bilki, B. and Clarida, W. Dilsiz, K. Durgut, S. Gandrajula, R. P. and Haytmyradov, M. Khristenko, V Merlo, J-P Mermerkaya, H. and Mestvirishvili, A. Moeller, A. Nachtman, J. Ogul, H. and Onel, Y. Ozok, F. Penzo, A. Snyder, C. Tiras, E. and Wetzel, J. Yi, K. Blumenfeld, B. Cocoros, A. Eminizer, N. Fehling, D. Feng, L. Gritsan, V, A. Maksimovic, P. and Roskes, J. Sarica, U. Swartz, M. Xiao, M. You, C. and Al-bataineh, A. Baringer, P. Bean, A. Boren, S. and Bowen, J. Castle, J. Khalil, S. Kropivnitskaya, A. and Majumder, D. Mcbrayer, W. Murray, M. Royon, C. Sanders, S. Schmitz, E. Stringer, R. Takaki, J. D. Tapia Wang, Q. and Ivanov, A. Kaadze, K. Maravin, Y. Mohammadi, A. and Saini, L. K. Skhirtladze, N. Toda, S. Rebassoo, F. and Wright, D. Anelli, C. Baden, A. Baron, O. Belloni, A. and Calvert, B. Eno, S. C. Ferraioli, C. Hadley, N. J. and Jabeen, S. Jeng, G. Y. Kellogg, R. G. Kunkle, J. and Mignerey, A. C. Ricci-Tam, F. Shin, Y. H. Skuja, A. and Tonwar, S. C. Abercrombie, D. Allen, B. Azzolini, V and Barbieri, R. Baty, A. Bi, R. Brandt, S. Busza, W. and Cali, I. A. D'Alfonso, M. Demiragli, Z. Ceballos, G. Gomez and Goncharov, M. Hsu, D. Iiyama, Y. Innocenti, G. M. and Klute, M. Kovalskyi, D. Lai, Y. S. Lee, Y-J Levin, A. and Luckey, P. D. Maier, B. Marini, A. C. Mcginn, C. and Mironov, C. Narayanan, S. Niu, X. Paus, C. Roland, C. and Roland, G. Salfeld-Nebgen, J. Stephans, G. S. F. Tatar, K. Velicanu, D. Wang, T. W. Wyslouch, B. Benvenuti, A. C. Chatterjee, R. M. Evans, A. Hansen, P. Kalafut, S. and Kubota, Y. Lesko, Z. Mans, J. Nourbakhsh, S. and Ruckstuhl, N. Rusack, R. Turkewitz, J. Acosta, J. G. and Oliveros, S. Avdeeva, E. Bloom, K. Claes, D. R. and Fangmeier, C. Suarez, R. Gonzalez Kamalieddin, R. and Kravchenko, I Monroy, J. Siado, J. E. Snow, G. R. and Stieger, B. Alyari, M. Dolen, J. Godshalk, A. and Harrington, C. Iashvili, I. Nguyen, D. Parker, A. and Rappoccio, S. Roozbahani, B. Alverson, G. Barberis, E. and Hortiangtham, A. Massironi, A. Morse, D. M. Nash, D. and Orimoto, T. De Lima, R. Teixeira Trocino, D. Wood, D. and Charaf, O. Hahn, K. A. Mucia, N. Odell, N. Pollack, B. and Schmitt, M. H. Sung, K. Trovato, M. Velasco, M. Dev, N. Hildreth, M. Anampa, K. Hurtado Jessop, C. Karmgard, D. J. Kellams, N. Lannon, K. Loukas, N. Marinelli, N. and Meng, F. Mueller, C. Musienko, Y. Planer, M. and Reinsvold, A. Ruchti, R. Smith, G. Taroni, S. Wayne, M. and Wolf, M. Woodard, A. Alimena, J. Antonelli, L. and Bylsma, B. Durkin, L. S. Flowers, S. Francis, B. Hart, A. Hill, C. Ji, W. Liu, B. Luo, W. Puigh, D. and Winer, B. L. Wulsin, H. W. Benaglia, A. Cooperstein, S. and Driga, O. Elmer, P. Hardenbrook, J. Hebda, P. and Higginbotham, S. Lange, D. Luo, J. Marlow, D. Mei, K. and Ojalvo, I Olsen, J. Palmer, C. Piroue, P. Stickland, D. Tully, C. Norberg, S. Barker, A. Barnes, V. E. and Folgueras, S. Gutay, L. Jha, M. K. Jones, M. Jung, A. W. and Khatiwada, A. Miller, D. H. Neumeister, N. Peng, C. C. and Schulte, J. F. Sun, J. Wang, F. Xie, W. Cheng, T. and Parashar, N. Stupak, J. Adair, A. Akgun, B. Chen, Z. and Ecklund, K. M. Geurts, F. J. M. Guilbaud, M. Li, W. and Michlin, B. Northup, M. Padley, B. P. Roberts, J. Rorie, J. Tu, Z. Zabel, J. Bodek, A. de Barbaro, P. Demina, R. Duh, Y. T. Ferbel, T. Galanti, M. Garcia-Bellido, A. and Han, J. Hindrichs, O. Khukhunaishvili, A. Lo, K. H. and Tan, P. Verzetti, M. Ciesielski, R. Goulianos, K. and Mesropian, C. Agapitos, A. Chou, J. P. Gershtein, Y. and Espinosa, T. A. Gomez Halkiadakis, E. Heindl, M. Hughes, E. and Kaplan, S. Elayavalli, R. Kunnawalkam Kyriacou, S. Lath, A. Montalvo, R. Nash, K. Osherson, M. Saka, H. and Salur, S. Schnetzer, S. Sheffield, D. Somalwar, S. and Stone, R. Thomas, S. Thomassen, P. Walker, M. Delannoy, A. G. Foerster, M. Heideman, J. Riley, G. Rose, K. and Spanier, S. Thapa, K. Bouhali, O. Hernandez, A. Castaneda and Celik, A. Dalchenko, M. De Mattia, M. Delgado, A. and Dildick, S. Eusebi, R. Gilmore, J. Huang, T. Kamon, T. and Mueller, R. Pakhotin, Y. Patel, R. Perloff, A. and Pernie, L. Rathjens, D. Safonov, A. Tatarinov, A. Ulmer, K. A. Akchurin, N. Damgov, J. De Guio, F. Dudero, P. R. and Faulkner, J. Gurpinar, E. Kunori, S. Lamichhane, K. and Libeiro, T. Peltola, T. Undleeb, S. Volobouev, I Greene, S. Gurrola, A. Janjam, R. Johns, W. Maguire, C. and Melo, A. Ni, H. Sheldon, P. Tuo, S. Velkovska, J. and Xu, Q. Arenton, M. W. Barria, P. Cox, B. Hirosky, R. and Ledovskoy, A. Li, H. Neu, C. Sinthuprasith, T. Sun, X. and Wang, Y. Wolfe, E. Xia, F. Harr, R. Karchin, P. E. and Sturdy, J. Zaleski, S. Brodski, M. Buchanan, J. and Caillol, C. Dasu, S. Dodd, L. Duric, S. Gomber, B. and Grothe, M. Herndon, M. Herve, A. Hussain, U. Klabbers, P. Lanaro, A. Levine, A. Long, K. Loveless, R. and Pierro, G. A. Polese, G. Ruggles, T. Savin, A. Smith, N. and Smith, W. H. Taylor, D. Woods, N. CMS Collaboration

Subjects
Physics::Instrumentation and Detectors, Nuclear Experiment
Abstract

Quantum-statistical (Bose-Einstein) two-particle correlations are measured in pp collisions at root s = 0.9, 2.76, and 7 TeV, as well as in pPb and peripheral PbPb collisions at nucleon-nucleon center-of-mass energies of 5.02 and 2.76 TeV, respectively, using the CMS detector at the Large Hadron Collider. Separate analyses are performed for same-sign unidentified charged particles as well as for same-sign pions and kaons identified via their energy loss in the silicon tracker. The characteristics of the one-, two-, and three-dimensional correlation functions are studied as functions of the pair average transverse momentum (k(T)) and the charged-particle multiplicity in the event. For all systems, the extracted correlation radii steadily increase with the event multiplicity, and decrease with increasing k(T). The radii are in the range 1-5 fm, the largest values corresponding to very high multiplicity pPb interactions and to peripheral PbPb collisions with multiplicities similar to those seen in pPb data. It is also observed that the dependencies of the radii on multiplicity and k(T) largely factorize. At the same multiplicity, the radii are relatively independent of the colliding system and center-of-mass energy.

Published
2018

42. Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study

Author

Milena Sant, Maria Dolores Chirlaque Lopez, Roberto Agresti, Maria José Sánchez Pérez, Bernd Holleczek, Magdalena Bielska-Lasota, Nadya Dimitrova, Kaire Innos, Alexander Katalinic, Hilde Langseth, Nerea Larrañaga, Silvia Rossi, Sabine Siesling, Pamela Minicozzi, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. Zvolský, L. Dušek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A.V. Guizard, J. Faivre, A.M. Bouvier, P. Arveux, M. Maynadié, A.S. Woronoff, M. Robaszkiewicz, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, M. Meyer, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Kieschke, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, P. Mancuso, S. Ferretti, E. Crocetti, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, R. Capocaccia, E. Carrani, S. Francisci, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, S. Busco, L. Bonelli, M. Vercelli, V. Gennaro, P. Ricci, M. Autelitano, G. Randi, M. Ponz De Leon, C. Marchesi, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, P. Giorgi Rossi, E. Di Felice, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, F. Bianconi, G. Tagliabue, P. Contiero, A.P. Dei Tos, S. Guzzinati, S. Pildava, G. Smailyte, N. Calleja, D. Agius, T.B. Johannesen, J. Rachtan, S. Gózdz, R. Mezyk, J. Blaszczyk, M. Bebenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, F. Nicula, D. Coza, C. Safaei Diba, M. Primic-Zakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, D.Y.L. Chang, C. Navarro, M.D. Chirlaque, C. Moreno-Iribas, E. Ardanaz, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Lemmens, M. Coleman, C. Allemani, B. Rachet, J. Verne, N. Easey, G. Lawrence, T. Moran, J. Rashbass, M. Roche, J. Wilkinson, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, R. Otter, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences

Subjects
Gynecology, Cervical cancer, Cancer Research, medicine.medical_specialty, education.field_of_study, Vaginal cancer, Relative survival, business.industry, Obstetrics, Population, Cancer, Breast cancer, Corpus uteri cancer, Europe, Ovarian cancer, Population-based, Survival, Vulval cancer, Vulvar cancer, medicine.disease, medicine.anatomical_structure, Oncology, medicine, METIS-311843, IR-97294, business, education, Cervix
Abstract

BACKGROUND: Survival differences across Europe for patients with cancers of breast, uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In the present EUROCARE-5 study we update survival estimates and investigate changes in country-specific and over time survival, discussing their relationship with incidence and mortality dynamics for cancers for which organised screening programs are ongoing. METHODS: We analysed cases archived in over 80 population-based cancer registries in 29 countries grouped into five European regions. We used the cohort approach to estimate 5-year relative survival (RS) for adult (⩾15years) women diagnosed 2000-2007, by age, country and region ; and the period approach to estimate time trends (1999-2007) in RS for breast and cervical cancers. RESULTS: In 2000-2007, 5-year RS was 57% overall, 82% for women diagnosed with breast, 76% with corpus uteri, 62% with cervical, 38% with ovarian, 40% with vaginal and 62% with vulvar cancer. Survival was low for patients resident in Eastern Europe (34% ovary-74% breast) and Ireland and the United Kingdom [Ireland/UK] (31-79%) and high for those resident in Northern Europe (41-85%) except Denmark. Survival decreased with advancing age: markedly for women with ovarian (71% 15-44years ; 20% ⩾75years) and breast (86% ; 72%) cancers. Survival for patients with breast and cervical cancers increased from 1999-2001 to 2005-2007, remarkably for those resident in countries with initially low survival. CONCLUSIONS: Despite increases over time, survival for women's cancers remained poor in Eastern Europe, likely due to advanced stage at diagnosis and/or suboptimum access to adequate care. Low survival for women living in Ireland/UK and Denmark could indicate late detection, possibly related also to referral delay. Poor survival for ovarian cancer across the continent and over time suggests the need for a major research effort to improve prognosis for this common cancer.

Published
2015
Full Text
View/download PDF

43. Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas

Author

Lidia Sacchetto, Sarah V. Ward, Marianne Berwick, Nancy E. Thomas, Colin B. Begg, Richard P. Gallagher, Klaus J. Busam, Anne E. Cust, Hoda Anton-Culver, P.A. Kanetsky, Bruce K. Armstrong, R. Zanetti, Gemma Cadby, Li Luo, David W. Ollila, David C. Gibbs, Stefano Rosso, Anne Kricker, and Irene Orlow

Subjects
Oncology, Male, medicine.medical_specialty, Pathology, Skin Neoplasms, Genotype, Dermatology, Polymorphism, Single Nucleotide, Article, Breslow Thickness, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, neoplasms, Melanoma, OCA2, business.industry, Genetic variants, Middle Aged, medicine.disease, Prognosis, Risk variant, 030220 oncology & carcinogenesis, Interferon Regulatory Factors, Female, business, IRF4
Abstract

Breslow thickness is considered to be the most important prognostic tumor feature in melanoma patients and is associated with age, sex, and phenotypic risk factors for melanoma such as number of nevi. However, its association with inherited genetic variants in recently identified melanoma risk loci is largely unknown. In a Western Australian Melanoma Health Study (WAMHS) study, published in the British Journal of Dermatology, IRF4 rs12203592, OCA2 rs1800401 and TP53 rs1042522 were significantly associated (P < 0.05) with Breslow thickness; however, these associations did not pass false discovery. This article is protected by copyright. All rights reserved.

Published
2017

44. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

Author

Pamela Minicozzi, Kaire Innos, Maria-José Sánchez, Annalisa Trama, Paul M. Walsh, Rafael Marcos-Gragera, Nadya Dimitrova, Laura Botta, Otto Visser, Silvia Rossi, Andrea Tavilla, Milena Sant, M. Hackl, N. Zielonke, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, L. Dušek, M. Zvolský, M. Mägi, T. Aareleid, N. Malila, K. Seppä, A.M. Bouvier, J. Faivre, N. Bossard, Z. Uhry, M. Colonna, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Heidrich, B. Holleczek, A. Katalinic, K. Clough-Gorr, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, S. Ferretti, A. Barchielli, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, R. Capocaccia, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, E. Carrani, S. Francisci, A. Knijn, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, R.A. Filiberti, E. Marani, M. Autelitano, G. Spagnoli, C. Cirilli, M. Fusco, M.F. Vitale, A. Traina, R. Staiti, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, F. Falcini, A.L. Caiazzo, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, M. Rugge, S. Tognazzo, S. Pildava, G. Smailyte, T.B. Johannesen, J. Rachtan, S. Góźdź, R. Mężyk, J. Błaszczyk, K. Kępska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, A. Lopez de Munain, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, L. Vilardell, C. Moreno-Iribas, E. Ardanaz, M. Lambe, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Damhuis, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Rashbass, J. Broggio, J. Verne, A. Gavin, D. Fitzpatrick, D.W. Huws, C. White, Minicozzi P., Innos K., Sanchez M.-J., Trama A., Walsh P.M., Marcos-Gragera R., Dimitrova N., Botta L., Visser O., Rossi S., Tavilla A., Sant M., Hackl M., Zielonke N., Van Eycken E., Henau K., Valerianova Z., Sekerija M., Dusek L., Zvolsky M., Magi M., Aareleid T., Malila N., Seppa K., Bouvier A.M., Faivre J., Bossard N., Uhry Z., Colonna M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Heidrich J., Holleczek B., Katalinic A., Clough-Gorr K., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Ferretti S., Barchielli A., Caldarella A., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Capocaccia R., Di Salvo F., Foschi R., Margutti C., Meneghini E., Serraino D., Maso L.D., De Angelis R., Caldora M., Carrani E., Francisci S., Knijn A., Mallone S., Pierannunzio D., Roazzi P., Santaquilani M., Pannozzo F., Natali M., Filiberti R.A., Marani E., Autelitano M., Spagnoli G., Cirilli C., Fusco M., Vitale M.F., Traina A., Staiti R., Vitale F., Cusimano R., Michiara M., Tumino R., Falcini F., Caiazzo A.L., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Rugge M., Tognazzo S., Pildava S., Smailyte G., Johannesen T.B., Rachtan J., Gozdz S., Mezyk R., Blaszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-da-Silva A., Safaei Diba C., Primic-Zakelj M., Almar E., Mateos A., Lopez de Munain A., Larranaga N., Torrella-Ramos A., Diaz Garcia J.M., Jimenez-Chillaron R., Vilardell L., Moreno-Iribas C., Ardanaz E., Lambe M., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Damhuis R., Otter R., Coleman M., Allemani C., Rachet B., Rashbass J., Broggio J., Verne J., Gavin A., Fitzpatrick D., Huws D.W., and White C.

Subjects
Male, medicine.medical_specialty, Cancer Research, Stage at diagnosi, Survival, Concordance, Cancer registrie, Cancer registries, Data quality, Stage at diagnosis, Socio-culturale, Reproducibility of Result, Predictive Value of Test, Data Accuracy, Europe, Female, Humans, Neoplasm Metastasis, Neoplasms, Predictive Value of Tests, Reproducibility of Results, Survival Analysis, Neoplasm Staging, Registries, Oncology, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, medicine, otorhinolaryngologic diseases, 030212 general & internal medicine, Stage (cooking), Intensive care medicine, Survival analysis, Cancer staging, business.industry, medicine.disease, Cancer registry, Clinical trial, Neoplasm Metastasi, 030220 oncology & carcinogenesis, Neoplasm, Survival Analysi, business, Human
Abstract

Background Cancer registries (CRs) are fundamental for estimating cancer burden, evaluating screening and monitoring health service performance. Stage at diagnosis—an essential information item collected by CRs—has been made available, for the first time, by CRs participating in EUROCARE-5. We analysed the quality of this information and estimated stage-specific survival across Europe for CRs with good data quality. Data and methods Sixty-two CRs sent stage (as TNM, condensed TNM or extent of disease) for 15 cancers diagnosed in 2000–2007. We assessed the quality, partly by comparing stage according to the three systems. We also developed procedures to reconstruct stage (categories: local, regional, metastatic and unknown) using information from all three systems, thus minimising the amount of missing information. Results Moderate-to-excellent stage concordance was found for practically all 24 CRs, for which it was possible to compare at least two staging systems. However, since stage was often incorrectly assigned, and information on the presence/absence of metastases was often lacking, data on only 7/15 cancers from 34/62 CRs (15 countries) were of sufficient quality for further analysis. Cases diagnosed ≥70 years had more advanced (or lacking) stage– and worse stage-specific survival than those Conclusions Many European CRs collect and record reasonably accurate stage information. Others have difficulties. Both the completeness of primary data and the accuracy of stage coding need to be improved in order for CRs to fulfil their expanding roles in cancer control. We propose our stage reconstruction/checking procedures as a means of fully exploiting the stage information provided by EUROCARE CRs. More advanced (or lacking) stage at diagnosis plus poorer stage-specific survival in the elderly are worrying.

Published
2017

46. Prophylactic Use of Ketorolac Tromethamine in Cataract Surgery: A Randomized Trial

Author

Maria Cecilia Machado, Rodrigo Pessoa Cavalcanti Lira, Carlos Eduardo Leite Arieta, Gustavo B. Rodrigues, Fernando R. Zanetti, and Flavia Gazze Ticly

Subjects
Male, medicine.medical_specialty, Intraocular pressure, Visual acuity, genetic structures, Prednisolone, medicine.medical_treatment, Anti-Inflammatory Agents, Visual Acuity, Cataract Extraction, Placebo, Ketorolac Tromethamine, Macular Edema, law.invention, Double-Blind Method, Randomized controlled trial, law, Ophthalmology, medicine, Humans, Pharmacology (medical), Prospective Studies, Macular edema, Aged, Pharmacology, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Diabetic retinopathy, Middle Aged, Cataract surgery, medicine.disease, eye diseases, Surgery, Treatment Outcome, Female, sense organs, Ophthalmic Solutions, medicine.symptom, business, Tomography, Optical Coherence, Follow-Up Studies
Abstract

To determine the efficacy of topical ketorolac tromethamine in preventing cystoid macular edema (CME) after uncomplicated cataract surgery.This single-center, prospective, double-masked, randomized clinical trial consisted of 81 patients who were scheduled for cataract surgery. Patients were randomized to receive hypromellose/dextran 70 as a placebo (n=44) or ketorolac tromethamine 0.4% (n=37) as an adjuvant therapy. These eye drops were administered 4 times daily (QID) for 3 days before surgery and 5 weeks postoperatively. All patients received prednisolone acetate 1% QID during the same period as basal/standard anti-inflammatory therapy. The primary outcome was the incidence of angiographic CME 5 weeks after surgery. The secondary outcomes were mean change in best-corrected visual acuity (BCVA) [Early Treatment Diabetic Retinopathy study (ETDRS)], clinical CME incidence, intraocular pressure, and retinal thickness measured using optical coherence tomography (OCT).In the placebo group, 2/44 (4.5%) patients and in the ketorolac group, 2/37 (5.4%) patients presented with angiographic CME (P=0.624). The mean change in postoperative BCVA was 32±15 letters in the placebo group and 26±16 letters in the ketorolac group (P=0.07). There were no statistically significant between-group differences in the mean central subfield thickness (P=0.679), minimal central thickness (P=0.352), or central macular volume (P=0.729).There was no difference between ketorolac tromethamine and a placebo with regard to BCVA results or prevention of CME after uncomplicated cataract surgery.

Published
2014
Full Text
View/download PDF

47. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

Author

L. Dal Maso, A. Tavilla, F. Pacini, D. Serraino, B.A.C. van Dijk, M.D. Chirlaque, R. Capocaccia, N. Larrañaga, M. Colonna, D. Agius, E. Ardanaz, J. Rubió-Casadevall, A. Kowalska, S. Virdone, S. Mallone, H. Amash, R. De Angelis, M. Hackl, N. Zielonke, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, L. Dušek, M. Zvolský, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, A.V. Guizard, J. Faivre, A.S. Woronoff, B. Tretarre, N. Bossard, Z. Uhry, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre-Ledoux, P. Grosclaude, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Heidrich, B. Holleczek, A. Katalinic, J.G. Jónasson, L. Tryggvadóttir, H. Comber, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, A. Sutera Sardo, A. Mazzei, S. Ferretti, A. Barchielli, A. Caldarella, G. Gatta, M. Sant, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, A. Zucchetto, M. Caldora, E. Carrani, S. Francisci, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, F. Pannozzo, S. Busco, R.A. Filiberti, M. Vercelli, P. Ricci, M. Autelitano, G. Spagnoli, C. Cirilli, M. Fusco, M.F. Vitale, M. Usala, F. Vitale, B. Ravazzolo, M. Michiara, R. Tumino, L. Mangone, M. Vicentini, F. Falcini, A. Iannelli, O. Sechi, R. Cesaraccio, S. Piffer, A. Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, P. Candela, T. Scuderi, F. Stracci, A. Rocca, G. Tagliabue, P. Contiero, M. Rugge, S. Tognazzo, S. Pildava, G. Smailyte, N. Calleja, T.B. Johannesen, J. Rachtan, S. Góźdź, R. Mężyk, J. Błaszczyk, M. Bębenek, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, C. Castro, A. Miranda, A. Mayer-da-Silva, C. Safaei Diba, M. Primic-Zakelj, M. Errezola, J. Bidaurrazaga, J.M. Díaz García, A.I. Marcos-Navarro, R. Marcos-Gragera, A. Izquierdo Font, M.J. Sanchez, E. Molina, C. Navarro, C. Moreno-Iribas, J. Galceran, M. Carulla, M. Lambe, S. Khan, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, V. Ho, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Rashbass, J. Broggio, J. Verne, A. Gavin, C. Donnelly, D.H. Brewster, D.W. Huws, C. White, Registre des cancers du Tarn, France, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Registre général des cancers du Tarn, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Dal Maso L., Tavilla A., Pacini F., Serraino D., van Dijk B.A.C., Chirlaque M.D., Capocaccia R., Larranaga N., Colonna M., Agius D., Ardanaz E., Rubio-Casadevall J., Kowalska A., Virdone S., Mallone S., Amash H., De Angelis R., Hackl M., Zielonke N., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Dusek L., Zvolsky M., Storm H., Engholm G., Magi M., Aareleid T., Malila N., Seppa K., Velten M., Guizard A.V., Faivre J., Woronoff A.S., Tretarre B., Bossard N., Uhry Z., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Heidrich J., Holleczek B., Katalinic A., Jonasson J.G., Tryggvadottir L., Comber H., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Sutera Sardo A., Ferretti S., Mazzei A., Caldarella A., Gatta G., Sant M., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Di Salvo F., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Zucchetto A., Caldora M., Carrani E., Francisci S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Pannozzo F., Busco S., Filiberti R.A., Vercelli M., Ricci P., Autelitano M., Spagnoli G., Cirilli C., Fusco M., Vitale M.F., Usala M., Vitale F., Ravazzolo B., Michiara M., Tumino R., Mangone L., Vicentini M., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Piffer S., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Candela P., Scuderi T., Stracci F., Rocca A., Tagliabue G., Contiero P., Rugge M., Tognazzo S., Pildava S., Smailyte G., Calleja N., Johannesen T.B., Rachtan J., Gozdz S., Mezyk R., Blaszczyk J., Bebenek M., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Castro C., Miranda A., Mayer-da-Silva A., Safaei Diba C., Primic-Zakelj M., Errezola M., Bidaurrazaga J., Diaz Garcia J.M., Marcos-Navarro A.I., Marcos-Gragera R., Izquierdo Font A., Sanchez M.J., Molina E., Navarro C., Moreno-Iribas C., Galceran J., Carulla M., Lambe M., Khan S., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Visser O., Ho V., Otter R., Coleman M., Allemani C., Rachet B., Rashbass J., Broggio J., Verne J., Gavin A., Donnelly C., Brewster D.H., Huws D.W., and White C.

Subjects
Registrie, Male, Cancer Research, IMPACT, Cancer registrie, [SDV]Life Sciences [q-bio], Papillary, 0302 clinical medicine, QUALITY-OF-LIFE, Residence Characteristics, Adenocarcinoma, Follicular, Cancer registries, Registries, Thyroid cancer, Thyroid Neoplasm, education.field_of_study, Relative survival, Incidence (epidemiology), Mortality rate, Incidence, Diagnosis-Related Group, EUROCARE, Europe, Adolescent, Adult, Aged, Carcinoma, Carcinoma, Papillary, Diagnosis-Related Groups, Female, Humans, Middle Aged, Sex Distribution, Thyroid Neoplasms, Young Adult, Oncology, PREVALENCE, 3. Good health, Thyroid Cancer, Papillary, 030220 oncology & carcinogenesis, Cohort, Human, medicine.medical_specialty, Population, GEOGRAPHICAL-DISTRIBUTION, UNITED-STATES, Socio-culturale, 030209 endocrinology & metabolism, Adenocarcinoma, RECENT TRENDS, 03 medical and health sciences, MANAGEMENT, medicine, education, Survival rate, business.industry, MORTALITY, Follicular, medicine.disease, Cancer registry, Surgery, MICROCARCINOMA, Residence Characteristic, business, Demography
Abstract

Background: Incidence rates of thyroid cancer (TC) increased in several countries during the last 30 years, while mortality rates remained unchanged, raising important questions for treatment and follow-up of TC patients. This study updates population-based estimates of relative survival (RS) after TC diagnosis in Europe by sex, country, age, period and histology.Methods: Data from 87 cancer registries in 29 countries were extracted from the EUROCARE-5 dataset. One-and 5-year RS were estimated using the cohort approach for 86,690 adult TC patients diagnosed in 2000-2007 and followed-up to 12/31/2008. RS trends in 1999-2007 and 10-year RS in 2005-2007 were estimated using the period approach.Results: In Europe 2000-2007, 5-year RS after TC was 88% in women and 81% in men. Survival rates varied by country and were strongly correlated (Pearson rho = 75%) with country-specific incidence rates. Five-year RS decreased with age (in women from > 95% at age 15-54 to 57% at age 75+), from 98% in women and 94% in men with papillary TC to 14% in women and 12% in men with anaplastic TC. Proportion of papillary TC varied by country and increased over time, while survival rates were similar across areas and periods. In 1999-2007, 5-year RS increased by five percentage points for all TCs but only by two for papillary and by four for follicular TC. Ten-year RS in 2005-2007 was 89% in women and 79% in men.Conclusions: The reported increasing TC survival trend and differences by area are mainly explained by the varying histological case-mix of cases. (C) 2017 Elsevier Ltd. All rights reserved.

Published
2017
Full Text
View/download PDF

49. Mass separation and in vitro immunological activity of membrane-fractionated polysaccharides from fruiting body and mycelium of Agaricus subrufescens

Author

Carlos R. Zanetti, Margarida Matos de Mendonça, Aguinaldo R. Pinto, Márcio José Rossi, Carla Maísa Camelini, Douglas Bardini Silveira, José Carlos Cunha Petrus, and Álvaro José Celmer

Subjects
chemistry.chemical_classification, biology, Biomedical Engineering, Ultrafiltration, Bioengineering, biology.organism_classification, Polysaccharide, Applied Microbiology and Biotechnology, In vitro, Microbiology, Immune system, Biochemistry, chemistry, medicine, biology.protein, Antibody, Agaricus subrufescens, Mycelium, Polymyxin B, Biotechnology, medicine.drug
Abstract

Membrane technology has been applied to separate polysaccharides from Agaricus subrufescens (ASPs). The membrane-retained fractions and unfractionated preparations have been tested for in vitro immunological activity. Both the microfiltration (MF) and ultrafiltration (UF1) membranes were able to separate high-molecular weight polysaccharides from fruiting body (ASP-FB) and submerge-fermented mycelium (ASP-SmF) extracts. All fractions showed immunostimulatory effects on RAW 264.7 macrophages, measured by TNF-α, iNOs gene expression, and NO production. In contrast, antibody and proliferation levels in B lymphoblastoid SKW 6.4 cells were significantly increased after treatment with ASP-FB, but did not with ASP-SmF preparations. The ASPs- and LPS-induced stimulation could be differentiated by the finding that polymyxin B, a specific inhibitor of LPS, did not significantly affect the immunoactivating response and proliferation activity of ASPs on macrophages and B cells, respectively. Furthermore, the ASP-FB treatment was unable to induce IL-6 production by B cells unlike LPS activation, sustaining distinct signaling pathways for ASP-FB and LPS. The overall results provided additional information about the action of ASPs on the immune system and support the membrane method to separate and concentrate high- molecular weight ASPs for immunopharmacological and biotechnological applications.

Published
2012
Full Text
View/download PDF

50. Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus

Author

Taisa Regina Stumpf, Rosendo A. Yunes, Ricardo José Nunes, Elza de Fátima Albino Smânia, Artur Smânia, Franco Delle Monache, Douglas Bardini Silveira, Lucas Ariel Totaro Garcia, Célia Regina Monte Barardi, Carlos R. Zanetti, Aline Viancelli, Louise Domeneghini Chiaradia, Alessandra Mascarello, and Thaís Moreira Osório

Subjects
Methicillin-Resistant Staphylococcus aureus, Staphylococcus aureus, Clinical Biochemistry, Pharmaceutical Science, Context (language use), Microbial Sensitivity Tests, medicine.disease_cause, Staphylococcal infections, Biochemistry, Microbiology, Methicillin, Minimum inhibitory concentration, chemistry.chemical_compound, Chalcones, Antibiotic resistance, Chlorocebus aethiops, Drug Discovery, medicine, Animals, Humans, Vero Cells, Molecular Biology, Oxadiazoles, Chemistry, Organic Chemistry, Hydrazones, Dihydrochalcone, Staphylococcal Infections, medicine.disease, Methicillin-resistant Staphylococcus aureus, Anti-Bacterial Agents, Models, Chemical, Molecular Medicine, Antibacterial activity
Abstract

The increase in antibiotic resistance due to multiple factors has encouraged the search for new compounds which are active against multidrug-resistant pathogens. In this context, chalcones, dihydrochalcones, hydrazones and oxadiazoles were tested against Staphylococcus aureus ATCC 25923 and methicillin-resistant S. aureus (MRSA) isolates, which were obtained from clinical laboratories and were characterized as MRSA using traditional and molecular methods. Among 65 tested compounds, two chalcones, one dihydrochalcone and two hydrazones were active against MRSA. Based on the minimal inhibitory concentration and cytotoxicity, hydrazones provided a better selectivity index than chalcones. Active hydrazones are promising antibiotic-like substances and they should be the subject of further microbiological studies.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results